Back to Search Results
Image Place holder

Michael Vogelbaum, MD, PhD

Program Leader, Department of Neuro-Oncology
Chief of Neurosurgery

★★★★★
★★★★★
5 (32 ratings)
Specialty: Neurosurgery
Program: Neuro-Oncology

Call 1-888-663-3488

Call 1-888-663-3488


Locations:
Overview

Cancer Focus: Brain Cancer, Glioblastoma, Neurofibromatosis

Dr. Vogelbaum is an internationally known leader in neurosurgical oncology and distinguished investigator in laboratory research, translational and clinical trials in gliomas, a dangerous type of brain cancer.  Dr. Vogelbaum is currently Chief of Neurosurgery and Program Leader of the Department of Neuro-Oncology at Moffitt Cancer Center.  He has served on or led numerous scientific committees and holds an array of honors and awards, as well as leadership positions at the regional, national and international level.  He is the principal investigator and co-investigator of a broad range of early phase investigator-initiated therapeutic trials, both national and international multisite collaborative studies. He has published over 190 peer-reviewed and invited articles.  He has written nine book chapters and co-edited one book: “Principles and Practice of Neuro-Oncology – A Multidisciplinary Approach.”  He was the recipient of the prestigious American Association of Neurological Surgeons Young Clinician Investigator Award.  Dr.  Vogelbaum also is the inventor of patented medical devices for delivering therapeutics directly to the brain and brain tumors.  The first of these devices has received FDA clearance. After completing his MD and PhD (Biomedical Engineering) at the University of Virginia, Dr. Vogelbaum completed his residency in neurological surgery at Barnes-Jewish Hospital in St. Louis, MO. He spent almost two decades at the Cleveland Clinic Foundation, where he developed recognition as a world-renowned expert in the diagnosis and treatment of benign and malignant tumors of the brain and spinal cord. He is a clinical/translational research scientist with particular expertise and academic interest in stereotactic (image-guided) brain surgery, radiosurgery, the biology of brain tumors, and the development of novel anti-cancer treatments. He has received support and funding from the American Cancer Society, the National Institutes of Health and the Wolf Family Foundation.


Education & Training

Residency:

  • Barnes-Jewish Hospital - Neurological Surgery
  • Barnes Hospital - Neurological Surgery

Medical School:

  • University of Virginia - M.D.
Participating Trials

If you believe you are eligible for one of these trials or studies, please call
813-745-6100 or toll-free 1-800-679-0775.

Publications

  • Karschnia P, Young JS, Dono A, Häni L, Sciortino T, Bruno F, Juenger ST, Teske N, Morshed RA, Haddad AF, Zhang Y, Stoecklein S, Weller M, Vogelbaum MA, Beck J, Tandon N, Hervey-Jumper S, Molinaro AM, Rudà R, Bello L, Schnell O, Esquenazi Y, Ruge MI, Grau SJ, Berger MS, Chang SM, van den Bent M, Tonn JC. Prognostic validation of a new classification system for extent of resection in glioblastoma: A report of the RANO resect group. Neurooncol. 2023 May.25(5):940-954. Pubmedid: 35961053. Pmcid: PMC10158281.
  • Bayik D, Bartels CF, Lovrenert K, Watson DC, Zhang D, Kay K, Lee J, Lauko A, Johnson S, Lo A, Silver DJ, McGraw M, Grabowski M, Mohammadi AM, Veglia F, Fan Y, Vogelbaum MA, Scacheri P, Lathia JD. Correction: Distinct Cell Adhesion Signature Defines Glioblastoma Myeloid-Derived Suppressor Cell Subsets. Cancer Res. 2023 May.83(10):1757. Pubmedid: 37183658. Pmcid: PMC10183804.
  • Rogers CL, Pugh SL, Vogelbaum MA, Perry A, Ashby LS, Modi JM, Alleman AM, Barani IJ, Braunstein S, Bovi JA, de Groot JF, Whitton AC, Lindhorst SM, Deb N, Shrieve DC, Shu HK, Bloom B, Machtay M, Mishra MV, Robinson CG, Won M, Mehta MP. Low-risk meningioma: Initial outcomes from NRG Oncology/RTOG 0539. Neurooncol. 2023 Jan.25(1):137-145. Pubmedid: 35657335. Pmcid: PMC9825319.
  • Ellingson BM, Wen PY, Chang SM, van den Bent M, Vogelbaum MA, Li G, Li S, Kim J, Youssef G, Wick W, Lassman AB, Gilbert MR, de Groot JF, Weller M, Galanis E, Cloughesy TF. Objective response rate (ORR) targets for recurrent glioblastoma clinical trials based on the historic association between ORR and median overall survival. Neurooncol. 2023 Jan. Pubmedid: 36617262.
  • Sampson JH, Singh Achrol A, Aghi MK, Bankiewiecz K, Bexon M, Brem S, Brenner A, Chandhasin C, Chowdhary S, Coello M, Ellingson BM, Floyd JR, Han S, Kesari S, Mardor Y, Merchant F, Merchant N, Randazzo D, Vogelbaum M, Vrionis F, Wembacher-Schroeder E, Zabek M, Butowski N. Targeting the IL4 Receptor with MDNA55 in Patients with Recurrent Glioblastoma: Results of a Phase 2b Trial. Neurooncol. 2023 Jan. Pubmedid: 36640127.
  • Pati S, Baid U, Edwards B, Sheller M, Wang SH, Reina GA, Foley P, Gruzdev A, Karkada D, Davatzikos C, Sako C, Ghodasara S, Bilello M, Mohan S, Vollmuth P, Brugnara G, Preetha CJ, Sahm F, Maier-Hein K, Zenk M, Bendszus M, Wick W, Calabrese E, Rudie J, Villanueva-Meyer J, Cha S, Ingalhalikar M, Jadhav M, Pandey U, Saini J, Garrett J, Larson M, Jeraj R, Currie S, Frood R, Fatania K, Huang RY, Chang K, Balaña C, Capellades J, Puig J, Trenkler J, Pichler J, Necker G, Haunschmidt A, Meckel S, Shukla G, Liem S, Alexander GS, Lombardo J, Palmer JD, Flanders AE, Dicker AP, Sair HI, Jones CK, Venkataraman A, Jiang M, So TY, Chen C, Heng PA, Dou Q, Kozubek M, Lux F, Michálek J, Matula P, Keřkovský M, Kopřivová T, Dostál M, Vybíhal V, Vogelbaum MA, Mitchell JR, Farinhas J, Maldjian JA, Yogananda CGB, Pinho MC, Reddy D, Holcomb J, Wagner BC, Ellingson BM, Cloughesy TF, Raymond C, Oughourlian T, Hagiwara A, Wang C, To MS, Bhardwaj S, Chong C, Agzarian M, Falcão AX, Martins SB, Teixeira BCA, Sprenger F, Menotti D, Lucio DR, LaMontagne P, Marcus D, Wiestler B, Kofler F, Ezhov I, Metz M, Jain R, Lee M, Lui YW, McKinley R, Slotboom J, Radojewski P, Meier R, Wiest R, Murcia D, Fu E, Haas R, Thompson J, Ormond DR, Badve C, Sloan AE, Vadmal V, Waite K, Colen RR, Pei L, Ak M, Srinivasan A, Bapuraj JR, Rao A, Wang N, Yoshiaki O, Moritani T, Turk S, Lee J, Prabhudesai S, Morón F, Mandel J, Kamnitsas K, Glocker B, Dixon LVM, Williams M, Zampakis P, Panagiotopoulos V, Tsiganos P, Alexiou S, Halia ...
  • Lassman AB, Pugh SL, Wang TJC, Aldape K, Gan HK, Preusser M, Vogelbaum MA, Sulman EP, Won M, Zhang P, Moazami G, Macsai MS, Gilbert MR, Bain EE, Blot V, Ansell PJ, Samanta S, Kundu MG, Armstrong TS, Wefel JS, Seidel C, de Vos FY, Hsu S, Cardona AF, Lombardi G, Bentsion D, Peterson RA, Gedye C, Bourg V, Wick A, Curran WJ, Mehta MP. Depatuxizumab mafodotin in EGFR-amplified newly diagnosed glioblastoma: A phase III randomized clinical trial. Neurooncol. 2023 Feb.25(2):339-350. Pubmedid: 35849035. Pmcid: PMC9925712.
  • Karschnia P, Young JS, Dono A, Häni L, Juenger ST, Sciortino T, Bruno F, Teske N, Morshed RA, Haddad AF, Zhang Y, Stoecklein S, Vogelbaum MA, Beck J, Tandon N, Hervey-Jumper S, Molinaro AM, Rudà R, Bello L, Schnell O, Esquenazi Y, Ruge MI, Grau SJ, van den Bent M, Weller M, Berger MS, Chang SM, Tonn JC. TERT promotor status does not add prognostic information in IDH-wildtype glioblastomas fulfilling other diagnostic WHO criteria: A report of the RANO resect group. Neurooncol Adv. 2022 Sep.4(1):vdac158. Pubmedid: 36325373. Pmcid: PMC9616057.
  • Law V, Chen Z, Vena F, Smalley I, Macaulay R, Evernden BR, Tran N, Pina Y, Puskas J, Caceres G, Bayle S, Johnson J, Liu JKC, Etame A, Vogelbaum M, Rodriguez P, Duckett D, Czerniecki B, Chen A, Smalley KSM, Forsyth PA. A preclinical model of patient-derived cerebrospinal fluid circulating tumor cells for experimental therapeutics in leptomeningeal disease from melanoma. Neurooncol. 2022 Oct.24(10):1673-1686. Pubmedid: 35213727. Pmcid: PMC9527526.
  • Morris BB, Smith JP, Zhang Q, Jiang Z, Hampton OA, Churchman ML, Arnold SM, Owen DH, Gray JE, Dillon PM, Soliman HH, Stover DG, Colman H, Chakravarti A, Shain KH, Silva AS, Villano JL, Vogelbaum MA, Borges VF, Akerley WL, Gentzler RD, Hall RD, Matsen CB, Ulrich CM, Post AR, Nix DA, Singer EA, Larner JM, Stukenberg PT, Jones DR, Mayo MW. Replicative Instability Drives Cancer Progression. Biomolecules. 2022 Oct.12(11). Pubmedid: 36358918. Pmcid: PMC9688014.
  • Lathia JD, Bayik D, Bartels CF, Lovrenert K, Watson DC, Zhang D, Kay K, Lee J, Lauko A, Johnson S, Lo A, Silver DJ, McGraw M, Grabowski MM, Mohammadi AM, Veglia F, Fan Y, Vogelbaum MA, Scacheri PC. Distinct Cell Adhesion Signature Defines Glioblastoma Myeloid-Derived Suppressor Cell Subsets. Cancer Res. 2022 Nov.82(22):4274-4287. Pubmedid: 36126163. Pmcid: PMC9664137.
  • Liu JKC, Kang R, Bilenkin A, Prorok R, Whiting J, Patel KB, Beer-Furlan A, Naso C, Rogers A, Castro XB, Peguero E, Mokhtari S, Tran N, Etame A, Pina Y, Spiess PE, Forsyth P, Vogelbaum MA. Patient satisfaction and cost savings analysis of the telemedicine program within a neuro-oncology department. J Neurooncol. 2022 Nov.160(2):517-525. Pubmedid: 36367630. Pmcid: PMC9651094.
  • Vogelbaum MA. Balancing maximal resection and functional preservation in surgery for low-grade glioma. Neurooncol. 2022 May.24(5):794-795. Pubmedid: 35020909. Pmcid: PMC9071335.
  • Rubino S, Oliver DE, Tran ND, Vogelbaum MA, Forsyth PA, Yu HM, Ahmed K, Etame AB. Improving Brain Metastases Outcomes Through Therapeutic Synergy Between Stereotactic Radiosurgery and Targeted Cancer Therapies. Front Oncol. 2022 Mar.12:854402. Pubmedid: 35311078. Pmcid: PMC8924127.
  • Soffietti R, Bettegowda C, Mellinghoff IK, Warren KE, Ahluwalia MS, De Groot JF, Galanis E, Gilbert MR, Jaeckle KA, Le Rhun E, Rudà R, Seoane J, Thon N, Umemura Y, Weller M, van den Bent MJ, Vogelbaum MA, Chang SM, Wen PY. Liquid biopsy in gliomas: A RANO review and proposals for clinical applications. Neurooncol. 2022 Jun.24(6):855-871. Pubmedid: 34999836. Pmcid: PMC9159432.
  • Tesileanu CMS, Sanson M, Wick W, Brandes AA, Clement PM, Erridge SC, Vogelbaum MA, Nowak AK, Baurain JF, Mason WP, Wheeler H, Chinot OL, Gill S, Griffin M, Rogers L, Taal W, Rudà R, Weller M, McBain C, van Linde ME, Aldape K, Jenkins RB, Kros JM, Wesseling P, von Deimling A, Hoogstrate Y, de Heer I, Atmodimedjo PN, Dubbink HJJ, Brouwer RWW, van IJcken WFJ, Cheung KJ, Golfinopoulos V, Baumert BG, Gorlia T, French PJ, van den Bent MJ. Temozolomide and Radiotherapy versus Radiotherapy Alone in Patients with Glioblastoma, IDH-wildtype: Post Hoc Analysis of the EORTC Randomized Phase III CATNON Trial. Clin Cancer Res. 2022 Jun.28(12):2527-2535. Pubmedid: 35275197. Pmcid: PMC9297529.
  • Kim JT, Di L, Etame AB, Olson S, Vogelbaum MA, Tran ND. Use of virtual magnetic resonance imaging to compensate for brain shift during image-guided surgery: illustrative case. J Neurosurg Case Lessons. 2022 Jun.3(24):CASE21683. Pubmedid: 35733635. Pmcid: PMC9204912.
  • Lowe SR, Kunigelis K, Vogelbaum MA. Leveraging the neurosurgical operating room for therapeutic development in NeuroOncology. Adv Drug Deliv Rev. 2022 Jul.186:114337. Pubmedid: 35561836.
  • Schiff D, Messersmith H, Brastianos PK, Brown PD, Burri S, Dunn IF, Gaspar LE, Gondi V, Jordan JT, Maues J, Mohile N, Redjal N, Stevens GHJ, Sulman EP, van den Bent M, Wallace HJ, Zadeh G, Vogelbaum MA. Radiation Therapy for Brain Metastases: ASCO Guideline Endorsement of ASTRO Guideline. J Clin Oncol. 2022 Jul.40(20):2271-2276. Pubmedid: 35561283.
  • Mills MN, Potluri TK, Kawahara Y, Fahey M, Figura NB, Soyano AE, Washington IR, Diaz R, Oliver DE, Yu HM, Etame AB, Vogelbaum MA, Czerniecki BJ, Arrington JA, Sahebjam S, Forsyth PA, Soliman HH, Han HS, Ahmed KA. The presentation of brain metastases in melanoma, non-small cell lung cancer, and breast cancer and potential implications for screening brain MRIs. Breast Cancer Res Treat. 2022 Jan.191(1):209-217. Pubmedid: 34669082.
  • Rubino S, Lynes J, McBride P, Sahebjam S, Mokhtari S, Farinhas JM, Perry A, Macaulay R, Vogelbaum MA. NTRK3 gene fusion in an adult ganglioglioma: illustrative case. J Neurosurg Case Lessons. 2022 Jan.3(5). Pubmedid: 36130567. Pmcid: PMC9379748.
  • Vogelbaum MA, Brown PD, Messersmith H, Brastianos PK, Burri S, Cahill D, Dunn IF, Gaspar LE, Gatson NTN, Gondi V, Jordan JT, Lassman AB, Maues J, Mohile N, Redjal N, Stevens G, Sulman E, van den Bent M, Wallace HJ, Weinberg JS, Zadeh G, Schiff D. Treatment for Brain Metastases: ASCO-SNO-ASTRO Guideline. J Clin Oncol. 2022 Feb.40(5):492-516. Pubmedid: 34932393.
  • Pati S, Baid U, Edwards B, Sheller M, Wang SH, Reina GA, Foley P, Gruzdev A, Karkada D, Davatzikos C, Sako C, Ghodasara S, Bilello M, Mohan S, Vollmuth P, Brugnara G, Preetha CJ, Sahm F, Maier-Hein K, Zenk M, Bendszus M, Wick W, Calabrese E, Rudie J, Villanueva-Meyer J, Cha S, Ingalhalikar M, Jadhav M, Pandey U, Saini J, Garrett J, Larson M, Jeraj R, Currie S, Frood R, Fatania K, Huang RY, Chang K, Quintero CB, Capellades J, Puig J, Trenkler J, Pichler J, Necker G, Haunschmidt A, Meckel S, Shukla G, Liem S, Alexander GS, Lombardo J, Palmer JD, Flanders AE, Dicker AP, Sair HI, Jones CK, Venkataraman A, Jiang M, So TY, Chen C, Heng PA, Dou Q, Kozubek M, Lux F, Michálek J, Matula P, Keřkovský M, Kopřivová T, Dostál M, Vybíhal V, Vogelbaum MA, Mitchell JR, Farinhas J, Maldjian JA, Yogananda CGB, Pinho MC, Reddy D, Holcomb J, Wagner BC, Ellingson BM, Cloughesy TF, Raymond C, Oughourlian T, Hagiwara A, Wang C, To MS, Bhardwaj S, Chong C, Agzarian M, Falcão AX, Martins SB, Teixeira BCA, Sprenger F, Menotti D, Lucio DR, LaMontagne P, Marcus D, Wiestler B, Kofler F, Ezhov I, Metz M, Jain R, Lee M, Lui YW, McKinley R, Slotboom J, Radojewski P, Meier R, Wiest R, Murcia D, Fu E, Haas R, Thompson J, Ormond DR, Badve C, Sloan AE, Vadmal V, Waite K, Colen RR, Pei L, Ak M, Srinivasan A, Bapuraj JR, Rao A, Wang N, Yoshiaki O, Moritani T, Turk S, Lee J, Prabhudesai S, Morón F, Mandel J, Kamnitsas K, Glocker B, Dixon LVM, Williams M, Zampakis P, Panagiotopoulos V, Tsiganos P, Alexiou S, Ha ...
  • Moreno V, Sepulveda JM, Reardon DA, Pérez-Núñez Á, González León P, Hanna B, Filvaroff E, Aronchik I, Chang H, Amoroso B, Zuraek M, Sanchez-Perez T, Mendez C, Stephens D, Nikolova Z, Vogelbaum MA. Trotabresib, an oral potent bromodomain and extraterminal inhibitor, in patients with high-grade gliomas: a phase I, "window-of-opportunity" study. Neurooncol. 2022 Dec. Pubmedid: 36455228.
  • Lowe SR, Wang CP, Brisco A, Whiting J, Arrington J, Ahmed K, Yu M, Robinson T, Oliver D, Etame A, Tran N, Beer Furlan A, Sahebjam S, Mokhtari S, Piña Y, Macaulay R, Forsyth P, Vogelbaum MA, Liu JKC. Surgical and anatomic factors predict development of leptomeningeal disease in patients with melanoma brain metastases. Neurooncol. 2022 Aug.24(8):1307-1317. Pubmedid: 35092434. Pmcid: PMC9340645.
  • Stummer W, Holling M, Bendok BR, Vogelbaum MA, Cox A, Renfrow SL, Widhalm G, Ezrin A, DeSena S, Sackman ML, Wyse JW. The NXDC-MEN-301 Study on 5-ALA for Meningiomas Surgery: An Innovative Study Design for the Assessing the Benefit of Intra-Operative Fluorescence Imaging. Brain Sci. 2022 Aug.12(8). Pubmedid: 36009108. Pmcid: PMC9405714.
  • Lynes J, Flores-Milan G, Rubino S, Arrington J, Macaulay R, Liu JKC, Beer-Furlan A, Tran ND, Vogelbaum MA, Etame AB. Molecular determinants of outcomes in meningiomas. Front Oncol. 2022 Aug.12:962702. Pubmedid: 36033542. Pmcid: PMC9413043.
  • Vogelbaum MA, Li G, Heimberger AB, Lang FF, Fueyo J, Gomez-Manzano C, Sanai N. A Window of Opportunity to Overcome Therapeutic Failure in Neuro-Oncology. Am Soc Clin Oncol Educ Book. 2022 Apr.42:1-8. Pubmedid: 35580289.
  • Tesileanu CMS, van den Bent MJ, Sanson M, Wick W, Brandes AA, Clement PM, Erridge SC, Vogelbaum MA, Nowak AK, Baurain JF, Mason WP, Wheeler H, Chinot OL, Gill S, Griffin M, Rogers L, Taal W, Rudà R, Weller M, McBain C, van Linde ME, Sabedot TS, Hoogstrate Y, von Deimling A, de Heer I, van IJcken WFJ, Brouwer RWW, Aldape K, Jenkins RB, Dubbink HJ, Kros JM, Wesseling P, Cheung KJ, Golfinopoulos V, Baumert BG, Gorlia T, Noushmehr H, French PJ. Prognostic significance of genome-wide DNA methylation profiles within the randomized, phase 3, EORTC CATNON trial on non-1p/19q deleted anaplastic glioma. Neurooncol. 2021 Sep.23(9):1547-1559. Pubmedid: 33914057. Pmcid: PMC8408862.
  • Karschnia P, Le Rhun E, Vogelbaum MA, van den Bent M, Grau SJ, Preusser M, Soffietti R, von Baumgarten L, Westphal M, Weller M, Tonn JC. The evolving role of neurosurgery for central nervous system metastases in the era of personalized cancer therapy. Eur J Cancer. 2021 Oct.156:93-108. Pubmedid: 34425408.
  • Walbert T, Harrison RA, Schiff D, Avila EK, Chen M, Kandula P, Lee JW, Le Rhun E, Stevens GHJ, Vogelbaum MA, Wick W, Weller M, Wen PY, Gerstner ER. SNO and EANO practice guideline update: Anticonvulsant prophylaxis in patients with newly diagnosed brain tumors. Neurooncol. 2021 Nov.23(11):1835-1844. Pubmedid: 34174071. Pmcid: PMC8563323.
  • Vogelbaum MA, Kroll D, Etame A, Tran N, Liu J, Ford A, Sparr E, Kim Y, Forsyth P, Sahebjam S, Mokhtari S, Peguero E, Macaulay R. A Prospective Validation Study of the First 3D Digital Exoscope for Visualization of 5-ALA-Induced Fluorescence in High-Grade Gliomas. World Neurosurg. 2021 May.149:e498-e503. Pubmedid: 33561551.
  • Mills MN, Thawani C, Figura NB, Oliver DE, Soyano AE, Etame A, Robinson TJ, Liu JK, Vogelbaum MA, Forsyth PA, Czerniecki BJ, Soliman HH, Han HS, Yu HM, Ahmed KA. Breast cancer subtype predicts clinical outcomes after stereotactic radiation for brain metastases. J Neurooncol. 2021 May.152(3):591-601. Pubmedid: 33742358.
  • Karschnia P, Vogelbaum MA, van den Bent M, Cahill DP, Bello L, Narita Y, Berger MS, Weller M, Tonn JC. Evidence-based recommendations on categories for extent of resection in diffuse glioma. Eur J Cancer. 2021 May.149:23-33. Pubmedid: 33819718.
  • Mills MN, Naz A, Thawani C, Walker C, Figura NB, Kushchayev S, Oliver DE, Etame AB, Yu HM, Robinson TJ, Liu JKC, Vogelbaum MA, Forsyth PA, Czerniecki BJ, Soliman HH, Han HS, Ahmed KA. Capecitabine and stereotactic radiation in the management of breast cancer brain metastases. BMC Cancer. 2021 May.21(1):552. Pubmedid: 33992087. Pmcid: PMC8126143.
  • Jaeckle KA, Ballman KV, van den Bent M, Giannini C, Galanis E, Brown PD, Jenkins RB, Cairncross JG, Wick W, Weller M, Aldape KD, Dixon JG, Anderson SK, Cerhan JH, Wefel JS, Klein M, Grossman SA, Schiff D, Raizer JJ, Dhermain F, Nordstrom DG, Flynn PJ, Vogelbaum MA. CODEL: phase III study of RT, RT + TMZ, or TMZ for newly diagnosed 1p/19q codeleted oligodendroglioma. Analysis from the initial study design. Neurooncol. 2021 Mar.23(3):457-467. Pubmedid: 32678879. Pmcid: PMC7992874.
  • Mills MN, Walker C, Thawani C, Naz A, Figura NB, Kushchayev S, Etame A, Yu HM, Robinson TJ, Liu J, Vogelbaum MA, Forsyth PA, Czerniecki BJ, Soliman HH, Han HS, Ahmed KA. Trastuzumab Emtansine (T-DM1) and stereotactic radiation in the management of HER2+ breast cancer brain metastases. BMC Cancer. 2021 Mar.21(1):223. Pubmedid: 33663447. Pmcid: PMC7934378.
  • Tesileanu CMS, Vallentgoed WR, Sanson M, Taal W, Clement PM, Wick W, Brandes AA, Baurain JF, Chinot OL, Wheeler H, Gill S, Griffin M, Rogers L, Rudà R, Weller M, McBain C, Reijneveld J, Enting RH, Caparrotti F, Lesimple T, Clenton S, Gijtenbeek A, Lim E, de Vos F, Mulholland PJ, Taphoorn MJB, de Heer I, Hoogstrate Y, de Wit M, Boggiani L, Venneker S, Oosting J, Bovée JVMG, Erridge S, Vogelbaum MA, Nowak AK, Mason WP, Kros JM, Wesseling P, Aldape K, Jenkins RB, Dubbink HJ, Baumert B, Golfinopoulos V, Gorlia T, van den Bent M, French PJ. Non-IDH1-R132H IDH1/2 mutations are associated with increased DNA methylation and improved survival in astrocytomas, compared to IDH1-R132H mutations. Acta Neuropathol. 2021 Jun.141(6):945-957. Pubmedid: 33740099. Pmcid: PMC8113211.
  • van den Bent MJ, Tesileanu CMS, Wick W, Sanson M, Brandes AA, Clement PM, Erridge S, Vogelbaum MA, Nowak AK, Baurain JF, Mason WP, Wheeler H, Chinot OL, Gill S, Griffin M, Rogers L, Taal W, Rudà R, Weller M, McBain C, Reijneveld J, Enting RH, Caparrotti F, Lesimple T, Clenton S, Gijtenbeek A, Lim E, Herrlinger U, Hau P, Dhermain F, de Heer I, Aldape K, Jenkins RB, Dubbink HJ, Kros JM, Wesseling P, Nuyens S, Golfinopoulos V, Gorlia T, French P, Baumert BG. Adjuvant and concurrent temozolomide for 1p/19q non-co-deleted anaplastic glioma (CATNON; EORTC study 26053-22054): second interim analysis of a randomised, open-label, phase 3 study. Lancet Oncol. 2021 Jun.22(6):813-823. Pubmedid: 34000245. Pmcid: PMC8191233.
  • Ellingson BM, Sampson JH, Achrol AS, Aghi MK, Krystof Bankiewicz K, Wang C, Bexon M, Brem S, Brenner AJ, Chowdhary S, Floyd JR, Han SJ, Kesari S, Randazzo D, Vogelbaum MA, Vrionis FD, Zabek M, Butowski N, Coello M, Merchant N, Merchant F. Modified RANO, Immunotherapy RANO, and Standard RANO Response to Convection-Enhanced Delivery of IL4R-Targeted Immunotoxin MDNA55 in Recurrent Glioblastoma. Clin Cancer Res. 2021 Jul.27(14):3916-3925. Pubmedid: 33863808. Pmcid: PMC8282697.
  • Mansouri A, Beyn ME, Pancholi A, Chow CT, Wang R, Boutet A, Elias GJB, Germann J, Loh A, Voisin MR, Lozano AM, Chiocca EA, Vogelbaum MA, Zadeh G. Evolution of the Neurosurgeon's Role in Clinical Trials for Glioblastoma: A Systematic Overview of the Clinicaltrials.Gov Database. Neurosurgery. 2021 Jul.89(2):196-203. Pubmedid: 33989408.
  • Vogelbaum MA. Surgical Management of Glioblastoma: More Than Just Diagnosis and Decompression. Neurosurg Clin N Am. 2021 Jan.32(1):xiii-xxiv. Pubmedid: 33223032.
  • Hartnett S, Kroll D, Vogelbaum MA. Surgical Adjuncts for Glioblastoma. Neurosurg Clin N Am. 2021 Jan.32(1):83-91. Pubmedid: 33223029.
  • D'Amico RS, Aghi MK, Vogelbaum MA, Bruce JN. Convection-enhanced drug delivery for glioblastoma: a review. J Neurooncol. 2021 Feb.151(3):415-427. Pubmedid: 33611708. Pmcid: PMC8034832.
  • Vogelbaum MA, Parney IF, Elder JB, Cahill D. Neurosurgical involvement in clinical trials for CNS tumors. J Neurooncol. 2021 Feb.151(3):367-373. Pubmedid: 33611704.
  • Otvos B, Alban TJ, Grabowski MM, Bayik D, Mulkearns-Hubert EE, Radivoyevitch T, Rabljenovic A, Johnson S, Androjna C, Mohammadi AM, Barnett GH, Ahluwalia MS, Vogelbaum MA, Fecci PE, Lathia JD. Preclinical Modeling of Surgery and Steroid Therapy for Glioblastoma Reveals Changes in Immunophenotype that are Associated with Tumor Growth and Outcome. Clin Cancer Res. 2021 Apr.27(7):2038-2049. Pubmedid: 33542075. Pmcid: PMC8026586.
  • Kunigelis KE, Vogelbaum MA. Therapeutic Delivery to Central Nervous System. Neurosurg Clin N Am. 2021 Apr.32(2):291-303. Pubmedid: 33781509.
  • Mitchell JR, Kamnitsas K, Singleton KW, Whitmire SA, Clark-Swanson KR, Ranjbar S, Rickertsen CR, Johnston SK, Egan KM, Rollison DE, Arrington J, Krecke KN, Passe TJ, Verdoorn JT, Nagelschneider AA, Carr CM, Port JD, Patton A, Campeau NG, Liebo GB, Eckel LJ, Wood CP, Hunt CH, Vibhute P, Nelson KD, Hoxworth JM, Patel AC, Chong BW, Ross JS, Boxerman JL, Vogelbaum MA, Hu LS, Glocker B, Swanson KR. Deep neural network to locate and segment brain tumors outperformed the expert technicians who created the training data. J Med Imaging (Bellingham). 2020 Sep.7(5):055501. Pubmedid: 33102623. Pmcid: PMC7567400.
  • Vogelbaum MA, Krivosheya D, Borghei-Razavi H, Sanai N, Weller M, Wick W, Soffietti R, Reardon DA, Aghi MK, Galanis E, Wen PY, van den Bent M, Chang S. Phase 0 and window of opportunity clinical trial design in neuro-oncology: a RANO review. Neurooncol. 2020 Nov.22(11):1568-1579. Pubmedid: 32598442. Pmcid: PMC7690357.
  • Prager BC, Vasudevan HN, Dixit D, Bernatchez JA, Wu Q, Wallace LC, Bhargava S, Lee D, King BH, Morton AR, Gimple RC, Pekmezci M, Zhu Z, Siqueira-Neto JL, Wang X, Xie Q, Chen C, Barnett GH, Vogelbaum MA, Mack SC, Chavez L, Perry A, Raleigh DR, Rich JN. The Meningioma Enhancer Landscape Delineates Novel Subgroups and Drives Druggable Dependencies. Cancer Discov. 2020 Nov.10(11):1722-1741. Pubmedid: 32703768. Pmcid: PMC8194360.
  • Lee EQ, Weller M, Sul J, Bagley SJ, Sahebjam S, van den Bent M, Ahluwalia M, Campian JL, Galanis E, Gilbert MR, Holdhoff M, Lesser GJ, Lieberman FS, Mehta MP, Penas-Prado M, Schreck KC, Strowd RE, Vogelbaum MA, Walbert T, Chang SM, Nabors LB, Grossman S, Reardon DA, Wen PY. Optimizing eligibility criteria and clinical trial conduct to enhance clinical trial participation for primary brain tumor patients. Neurooncol. 2020 May.22(5):601-612. Pubmedid: 31974566. Pmcid: PMC7229255.
  • Rogers CL, Won M, Vogelbaum MA, Perry A, Ashby LS, Modi JM, Alleman AM, Galvin J, Fogh SE, Youssef E, Deb N, Kwok Y, Robinson CG, Shu HK, Fisher BJ, Panet-Raymond V, McMillan WG, de Groot JF, Zhang P, Mehta MP. High-risk Meningioma: Initial Outcomes From NRG Oncology/RTOG 0539. Int J Radiat Oncol Biol Phys. 2020 Mar.106(4):790-799. Pubmedid: 31786276. Pmcid: PMC7117785.
  • Sheikh S, Radivoyevitch T, Barnholtz-Sloan JS, Vogelbaum M. Long-term trends in glioblastoma survival: implications for historical control groups in clinical trials. Neurooncol Pract. 2020 Mar.7(2):158-163. Pubmedid: 32626584. Pmcid: PMC7318862.
  • Alban TJ, Bayik D, Otvos B, Rabljenovic A, Leng L, Jia-Shiun L, Roversi G, Lauko A, Momin AA, Mohammadi AM, Peereboom DM, Ahluwalia MS, Matsuda K, Yun K, Bucala R, Vogelbaum MA, Lathia JD. Glioblastoma Myeloid-Derived Suppressor Cell Subsets Express Differential Macrophage Migration Inhibitory Factor Receptor Profiles That Can Be Targeted to Reduce Immune Suppression. Front Immunol. 2020 Jun.11:1191. Pubmedid: 32625208. Pmcid: PMC7315581.
  • Muhsen BA, Joshi KC, Lee BS, Thapa B, Borghei-Razavi H, Jia X, Barnett GH, Chao ST, Mohammadi AM, Suh JH, Vogelbaum MA, Angelov L. The effect of Gamma Knife radiosurgery on large posterior fossa metastases and the associated mass effect from peritumoral edema. J Neurosurg. 2020 Jan.1-9. Pubmedid: 31978879.
  • Balasubramanian SK, Sharma M, Venur VA, Schmitt P, Kotecha R, Chao ST, Suh JH, Angelov L, Mohammadi AM, Vogelbaum MA, Barnett GH, Jia X, Pennell NA, Ahluwalia MS. Impact of EGFR mutation and ALK rearrangement on the outcomes of non-small cell lung cancer patients with brain metastasis. Neurooncol. 2020 Feb.22(2):267-277. Pubmedid: 31648302. Pmcid: PMC7442419.
  • Borghei-Razavi H, Sharma M, Emch T, Krivosheya D, Lee B, Muhsen B, Prayson R, Obuchowski N, Barnett GH, Vogelbaum MA, Chao ST, Suh JH, Mohammadi A, Angelov L. Pathologic Correlation of Cellular Imaging Using Apparent Diffusion Coefficient Quantification in Patients with Brain Metastases After Gamma Knife Radiosurgery. World Neurosurg. 2020 Feb.134:e903-e912. Pubmedid: 31733389.
  • Cloughesy TF, Petrecca K, Walbert T, Butowski N, Salacz M, Perry J, Damek D, Bota D, Bettegowda C, Zhu JJ, Iwamoto F, Placantonakis D, Kim L, Elder B, Kaptain G, Cachia D, Moshel Y, Brem S, Piccioni D, Landolfi J, Chen CC, Gruber H, Rao A, Hogan D, Accomando W, Ostertag D, Montellano TT, Kheoh T, Kabbinavar F, Vogelbaum MA. Effect of Vocimagene Amiretrorepvec in Combination With Flucytosine vs Standard of Care on Survival Following Tumor Resection in Patients With Recurrent High-Grade Glioma: A Randomized Clinical Trial. JAMA Oncol. 2020 Dec.6(12):1939-1946. Pubmedid: 33119048. Pmcid: PMC7596685.
  • Nwagwu CD, Immidisetti AV, Bukanowska G, Vogelbaum MA, Carbonell AM. Convection-Enhanced Delivery of a First-in-Class Anti-β1 Integrin Antibody for the Treatment of High-Grade Glioma Utilizing Real-Time Imaging. Pharmaceutics. 2020 Dec.13(1). Pubmedid: 33396712. Pmcid: PMC7823464.
  • Bayik D, Zhou Y, Park C, Hong C, Vail D, Silver DJ, Lauko A, Roversi G, Watson DC, Lo A, Alban TJ, McGraw M, Sorensen M, Grabowski MM, Otvos B, Vogelbaum MA, Horbinski C, Kristensen BW, Khalil AM, Hwang TH, Ahluwalia MS, Cheng F, Lathia JD. Myeloid-Derived Suppressor Cell Subsets Drive Glioblastoma Growth in a Sex-Specific Manner. Cancer Discov. 2020 Aug.10(8):1210-1225. Pubmedid: 32300059. Pmcid: PMC7415660.
  • Haider AS, van den Bent M, Wen PY, Vogelbaum MA, Chang S, Canoll PD, Horbinski CM, Huse JT. Toward a standard pathological and molecular characterization of recurrent glioma in adults: a Response Assessment in Neuro-Oncology effort. Neurooncol. 2020 Apr.22(4):450-456. Pubmedid: 31844891. Pmcid: PMC7158649.
  • Mills MN, Figura NB, Arrington JA, Yu HM, Etame AB, Vogelbaum MA, Soliman H, Czerniecki BJ, Forsyth PA, Han HS, Ahmed KA. Management of brain metastases in breast cancer: a review of current practices and emerging treatments. Breast Cancer Res Treat. 2020 Apr.180(2):279-300. Pubmedid: 32030570.
  • Amin-Hanjani S, Bambakidis NC, Barker FG, Carter BS, Cockroft KM, Du R, Fraser JF, Hamilton MG, Huang J, Jane JA, Jensen RL, Kaplitt MG, Kaufmann AM, Pilitsis JG, Riina HA, Schulder M, Vogelbaum MA, Yang LJS, Zada G. Editorial. COVID-19 and neurosurgical practice: an interim report. J Neurosurg. 2020 Apr.1-2. Pubmedid: 32330900. Pmcid: PMC7179965.
  • Lee EQ, Chukwueke UN, Hervey-Jumper SL, de Groot JF, Leone JP, Armstrong TS, Chang SM, Arons D, Oliver K, Verble K, Musella A, Willmarth N, Alexander BM, Bates A, Doherty L, Galanis E, Gaffey S, Halkin T, Friday BE, Fouladi M, Lin NU, Macdonald D, Mehta MP, Penas-Prado M, Vogelbaum MA, Sahebjam S, Sandak D, van den Bent M, Weller M, Reardon DA, Wen PY. Barriers to accrual and enrollment in brain tumor trials. Neurooncol. 2019 Sep.21(9):1100-1117. Pubmedid: 31175826. Pmcid: PMC7594546.
  • Vogelbaum MA. Editorial. Considering the role of surgery for low-grade glioma in the molecular genetic era. J Neurosurg. 2019 Oct.1-3. Pubmedid: 31653814.
  • Peereboom DM, Alban TJ, Grabowski MM, Alvarado AG, Otvos B, Bayik D, Roversi G, McGraw M, Huang P, Mohammadi AM, Kornblum HI, Radivoyevitch T, Ahluwalia MS, Vogelbaum MA, Lathia JD. Metronomic capecitabine as an immune modulator in glioblastoma patients reduces myeloid-derived suppressor cells. JCI Insight. 2019 Nov.4(22). Pubmedid: 31600167. Pmcid: PMC6948860.
  • Boire A, Brandsma D, Brastianos PK, Le Rhun E, Ahluwalia M, Junk L, Glantz M, Groves MD, Lee EQ, Lin N, Raizer J, Rudà R, Weller M, van den Bent MJ, Vogelbaum MA, Chang S, Wen PY, Soffietti R. Liquid biopsy in central nervous system metastases: a RANO review and proposals for clinical applications. Neurooncol. 2019 May.21(5):571-584. Pubmedid: 30668804. Pmcid: PMC6502489.
  • Kim JM, Miller JA, Kotecha R, Chao ST, Ahluwalia MS, Peereboom DM, Mohammadi AM, Barnett GH, Murphy ES, Vogelbaum MA, Angelov L, Abraham J, Moore H, Budd GT, Suh JH. Stereotactic radiosurgery with concurrent HER2-directed therapy is associated with improved objective response for breast cancer brain metastasis. Neurooncol. 2019 May.21(5):659-668. Pubmedid: 30726965. Pmcid: PMC6502492.
  • Chang SM, Messersmith H, Ahluwalia M, Andrews D, Brastianos PK, Gaspar LE, Gatson NTN, Jordan JT, Khasraw M, Lassman AB, Maues J, Mrugala M, Raizer J, Schiff D, Stevens G, Sumrall A, van den Bent M, Vogelbaum MA. Anticonvulsant Prophylaxis and Steroid Use in Adults With Metastatic Brain Tumors: ASCO and SNO Endorsement of the Congress of Neurological Surgeons Guidelines. J Clin Oncol. 2019 May.37(13):1130-1135. Pubmedid: 30883246. Pmcid: PMC7098828.
  • Mack SC, Singh I, Wang X, Hirsch R, Wu Q, Villagomez R, Bernatchez JA, Zhu Z, Gimple RC, Kim LJY, Morton A, Lai S, Qiu Z, Prager BC, Bertrand KC, Mah C, Zhou W, Lee C, Barnett GH, Vogelbaum MA, Sloan AE, Chavez L, Bao S, Scacheri PC, Siqueira-Neto JL, Lin CY, Rich JN. Chromatin landscapes reveal developmentally encoded transcriptional states that define human glioblastoma. J Exp Med. 2019 May.216(5):1071-1090. Pubmedid: 30948495. Pmcid: PMC6504206.
  • Chang SM, Messersmith H, Ahluwalia M, Andrews D, Brastianos PK, Gaspar LE, Gatson NTN, Jordan JT, Khasraw M, Lassman AB, Maues J, Mrugala M, Raizer J, Schiff D, Stevens G, Sumrall A, Van den Bent M, Vogelbaum MA. Anticonvulsant prophylaxis and steroid use in adults with metastatic brain tumors: summary of SNO and ASCO endorsement of the Congress of Neurological Surgeons guidelines. Neurooncol. 2019 Mar.21(4):424-427. Pubmedid: 30883663. Pmcid: PMC6422436.
  • Schiff D, van den Bent M, Vogelbaum MA, Wick W, Miller CR, Taphoorn M, Pope W, Brown PD, Platten M, Jalali R, Armstrong T, Wen PY. Recent developments and future directions in adult lower-grade gliomas: Society for Neuro-Oncology (SNO) and European Association of Neuro-Oncology (EANO) consensus. Neurooncol. 2019 Jul.21(7):837-853. Pubmedid: 30753579. Pmcid: PMC6620638.
  • Chang SM, Messersmith H, Vogelbaum MA. Anticonvulsant Prophylaxis and Steroid Use in Adults With Metastatic Brain Tumors: ASCO/SNO Joint Endorsement Summary of College of Neurologic Surgeons Guidelines. J Oncol Pract. 2019 Jul.15(7):395-397. Pubmedid: 31125284.
  • Huang RY, Bi WL, Weller M, Kaley T, Blakeley J, Dunn I, Galanis E, Preusser M, McDermott M, Rogers L, Raizer J, Schiff D, Soffietti R, Tonn JC, Vogelbaum M, Weber D, Reardon DA, Wen PY. Proposed response assessment and endpoints for meningioma clinical trials: report from the Response Assessment in Neuro-Oncology Working Group. Neurooncol. 2019 Jan.21(1):26-36. Pubmedid: 30137421. Pmcid: PMC6303427.
  • Juloori A, Miller JA, Parsai S, Kotecha R, Ahluwalia MS, Mohammadi AM, Murphy ES, Suh JH, Barnett GH, Yu JS, Vogelbaum MA, Rini B, Garcia J, Stevens GH, Angelov L, Chao ST. Overall survival and response to radiation and targeted therapies among patients with renal cell carcinoma brain metastases. J Neurosurg. 2019 Jan.1-9. Pubmedid: 30660120.
  • Huang RY, Bi WL, Griffith B, Kaufmann TJ, la Fougère C, Schmidt NO, Tonn JC, Vogelbaum MA, Wen PY, Aldape K, Nassiri F, Zadeh G, Dunn IF. Imaging and diagnostic advances for intracranial meningiomas. Neurooncol. 2019 Jan.21(Suppl 1):i44-i61. Pubmedid: 30649491. Pmcid: PMC6347083.
  • Whiting BB, Lee BS, Mahadev V, Borghei-Razavi H, Ahuja S, Jia X, Mohammadi AM, Barnett GH, Angelov L, Rajan S, Avitsian R, Vogelbaum MA. Combined use of minimal access craniotomy, intraoperative magnetic resonance imaging, and awake functional mapping for the resection of gliomas in 61 patients. J Neurosurg. 2019 Jan.1-9. Pubmedid: 30684941.
  • de Leeuw CN, Vogelbaum MA. Supratotal resection in glioma: a systematic review. Neurooncol. 2019 Feb.21(2):179-188. Pubmedid: 30321384. Pmcid: PMC6374756.
  • Parsai S, Miller JA, Juloori A, Chao ST, Kotecha R, Mohammadi AM, Ahluwalia MS, Murphy ES, Barnett GH, Vogelbaum MA, Angelov L, Peereboom DM, Suh JH. Stereotactic radiosurgery with concurrent lapatinib is associated with improved local control for HER2-positive breast cancer brain metastases. J Neurosurg. 2019 Feb.132(2):503-511. Pubmedid: 30738402.
  • Tom MC, Park DYJ, Yang K, Leyrer CM, Wei W, Jia X, Varra V, Yu JS, Chao ST, Balagamwala EH, Suh JH, Vogelbaum MA, Barnett GH, Prayson RA, Stevens GHJ, Peereboom DM, Ahluwalia MS, Murphy ES. Malignant Transformation of Molecularly Classified Adult Low-Grade Glioma. Int J Radiat Oncol Biol Phys. 2019 Dec.105(5):1106-1112. Pubmedid: 31461674.
  • Kotecha R, Kim JM, Miller JA, Juloori A, Chao ST, Murphy ES, Peereboom DM, Mohammadi AM, Barnett GH, Vogelbaum MA, Angelov L, Suh JH, Ahluwalia MS. The impact of sequencing PD-1/PD-L1 inhibitors and stereotactic radiosurgery for patients with brain metastasis. Neurooncol. 2019 Aug.21(8):1060-1068. Pubmedid: 30796838. Pmcid: PMC6682202.
  • Tom MC, Varra V, Leyrer CM, Park DY, Chao ST, Yu JS, Suh JH, Reddy CA, Balagamwala EH, Broughman JR, Kotagal KA, Vogelbaum MA, Barnett GH, Ahluwalia MS, Peereboom DM, Prayson RA, Stevens GHJ, Murphy ES. Risk Factors for Progression Among Low-Grade Gliomas After Gross Total Resection and Initial Observation in the Molecular Era. Int J Radiat Oncol Biol Phys. 2019 Aug.104(5):1099-1105. Pubmedid: 31022510.
  • Vogelbaum MA, Yu HM. Nodular leptomeningeal disease after surgery for a brain metastasis-should we be concerned?. Neurooncol. 2019 Aug.21(8):959-960. Pubmedid: 31051044. Pmcid: PMC6682200.
  • Lassman AB, Aldape KD, Ansell PJ, Bain E, Curran WJ, Eoli M, French PJ, Kinoshita M, Looman J, Mehta M, Muragaki Y, Narita Y, Ocampo C, Roberts-Rapp L, Song M, Vogelbaum MA, Walenkamp AME, Wang TJC, Zhang P, van den Bent MJ. Epidermal growth factor receptor (EGFR) amplification rates observed in screening patients for randomized trials in glioblastoma. J Neurooncol. 2019 Aug.144(1):205-210. Pubmedid: 31273577. Pmcid: PMC8082754.
  • Cloughesy TF, Landolfi J, Vogelbaum MA, Ostertag D, Elder JB, Bloomfield S, Carter B, Chen CC, Kalkanis SN, Kesari S, Lai A, Lee IY, Liau LM, Mikkelsen T, Nghiemphu P, Piccioni D, Accomando W, Diago OR, Hogan DJ, Gammon D, Kasahara N, Kheoh T, Jolly DJ, Gruber HE, Das A, Walbert T. Durable complete responses in some recurrent high-grade glioma patients treated with Toca 511 + Toca FC. Neurooncol. 2018 Sep.20(10):1383-1392. Pubmedid: 29762717. Pmcid: PMC6120351.
  • Abbassy M, Missios S, Barnett GH, Brewer C, Peereboom DM, Ahluwalia M, Neyman G, Chao ST, Suh JH, Vogelbaum MA. Phase I Trial of Radiosurgery Dose Escalation Plus Bevacizumab in Patients With Recurrent/Progressive Glioblastoma. Neurosurgery. 2018 Sep.83(3):385-392. Pubmedid: 28973311.
  • Sharma M, Schroeder JL, Elson P, Meola A, Barnett GH, Vogelbaum MA, Suh JH, Chao ST, Mohammadi AM, Stevens GHJ, Murphy ES, Angelov L. Outcomes and prognostic stratification of patients with recurrent glioblastoma treated with salvage stereotactic radiosurgery. J Neurosurg. 2018 Oct.131(2):489-499. Pubmedid: 30485180.
  • Alban TJ, Alvarado AG, Sorensen MD, Bayik D, Volovetz J, Serbinowski E, Mulkearns-Hubert EE, Sinyuk M, Hale JS, Onzi GR, McGraw M, Huang P, Grabowski MM, Wathen CA, Ahluwalia MS, Radivoyevitch T, Kornblum HI, Kristensen BW, Vogelbaum MA, Lathia JD. Global immune fingerprinting in glioblastoma patient peripheral blood reveals immune-suppression signatures associated with prognosis. JCI Insight. 2018 Nov.3(21). Pubmedid: 30385717. Pmcid: PMC6238746.
  • Miller JA, Kotecha R, Ahluwalia MS, Mohammadi AM, Suh JH, Barnett GH, Murphy ES, Vogelbaum MA, Angelov L, Chao ST. The impact of tumor biology on survival and response to radiation therapy among patients with non-small cell lung cancer brain metastases. Pract Radiat Oncol. 2018 Mar.7(4):e263-e273. Pubmedid: 28254368.
  • Murphy ES, Leyrer CM, Parsons M, Suh JH, Chao ST, Yu JS, Kotecha R, Jia X, Peereboom DM, Prayson RA, Stevens GHJ, Barnett GH, Vogelbaum MA, Ahluwalia MS. Risk Factors for Malignant Transformation of Low-Grade Glioma. Int J Radiat Oncol Biol Phys. 2018 Mar.100(4):965-971. Pubmedid: 29485076.
  • Arvold ND, Armstrong TS, Warren KE, Chang SM, DeAngelis LM, Blakeley J, Chamberlain MC, Dunbar E, Loong HH, Macdonald DR, Reardon DA, Vogelbaum MA, Yuan Y, Weller M, van den Bent M, Wen PY. Corticosteroid use endpoints in neuro-oncology: Response Assessment in Neuro-Oncology Working Group. Neurooncol. 2018 Jun.20(7):897-906. Pubmedid: 29788429. Pmcid: PMC6007454.
  • Rogers L, Zhang P, Vogelbaum MA, Perry A, Ashby LS, Modi JM, Alleman AM, Galvin J, Brachman D, Jenrette JM, De Groot J, Bovi JA, Werner-Wasik M, Knisely JPS, Mehta MP. Intermediate-risk meningioma: initial outcomes from NRG Oncology RTOG 0539. J Neurosurg. 2018 Jul.129(1):35-47. Pubmedid: 28984517. Pmcid: PMC5889346.
  • Kotecha R, Miller JA, Venur VA, Mohammadi AM, Chao ST, Suh JH, Barnett GH, Murphy ES, Funchain P, Yu JS, Vogelbaum MA, Angelov L, Ahluwalia MS. Melanoma brain metastasis: the impact of stereotactic radiosurgery, BRAF mutational status, and targeted and/or immune-based therapies on treatment outcome. J Neurosurg. 2018 Jul.129(1):50-59. Pubmedid: 28799876.
  • Bennett EE, Vogelbaum MA, Barnett GH, Angelov L, Chao S, Murphy E, Yu J, Suh JH, Elson P, Stevens GHJ, Mohammadi AM. Evaluation of Prognostic Factors for Early Mortality After Stereotactic Radiosurgery for Brain Metastases: a Single Institutional Retrospective Review. Neurosurgery. 2018 Jul.83(1):128-136. Pubmedid: 28673040.
  • Alexander BM, Brown PD, Ahluwalia MS, Aoyama H, Baumert BG, Chang SM, Gaspar LE, Kalkanis SN, Macdonald DR, Mehta MP, Soffietti R, Suh JH, van den Bent MJ, Vogelbaum MA, Wefel JS, Lee EQ, Wen PY. Clinical trial design for local therapies for brain metastases: a guideline by the Response Assessment in Neuro-Oncology Brain Metastases working group. Lancet Oncol. 2018 Jan.19(1):e33-e42. Pubmedid: 29304360.
  • Woody NM, Greer MD, Reddy CA, Videtic GMM, Chao ST, Murphy ES, Suh JH, Angelov L, Barnett GH, Vogelbaum MA, Stephans KL. Validation of the Disease-Specific GPA for Patients With 1 to 3 Synchronous Brain Metastases in Newly Diagnosed NSCLC. Clin Lung Cancer. 2018 Jan.19(1):e141-e147. Pubmedid: 28739316.
  • Rogers L, Zhang P, Vogelbaum MA, Mehta MP. Erratum. Intermediate-risk meningioma: initial outcomes from NRG Oncology RTOG 0539. J Neurosurg. 2018 Dec.129(6):1650. Pubmedid: 30485244.
  • Sharma M, Bellamkonda S, Mohapatra S, Meola A, Jia X, Mohammadi A, Angelov L, Barnett GH, Vogelbaum M, Ahluwalia MS. Correlation Between the Residual Tumor Volume, Extent of Tumor Resection, and O-Methylguanine DNA Methyltransferase Status in Patients with Glioblastoma. World Neurosurg. 2018 Aug.116:e147-e161. Pubmedid: 29709748.
  • Laufer I, Lo SS, Chang EL, Sheehan J, Guckenberger M, Sohn MJ, Ryu S, Foote M, Muacevic A, Soltys SG, Chao S, Myrehaug S, Gerszten PC, Lis E, Maralani P, Bilsky M, Fisher C, Rhines L, Verlaan JJ, Schiff D, Fehlings MG, Ma L, Chang S, Parulekar WR, Vogelbaum MA, Sahgal A. Population description and clinical response assessment for spinal metastases: part 2 of the SPIne response assessment in Neuro-Oncology (SPINO) group report. Neurooncol. 2018 Aug.20(9):1215-1224. Pubmedid: 29590465. Pmcid: PMC6071663.
  • Angelov L, Mohammadi AM, Bennett EE, Abbassy M, Elson P, Chao ST, Montgomery JS, Habboub G, Vogelbaum MA, Suh JH, Murphy ES, Ahluwalia MS, Nagel SJ, Barnett GH. Impact of 2-staged stereotactic radiosurgery for treatment of brain metastases ≥ 2 cm. J Neurosurg. 2018 Aug.129(2):366-382. Pubmedid: 28937324.
  • Vogelbaum MA. Targeted Therapies for Brain Tumors: Will They Ever Deliver?. Clin Cancer Res. 2018 Aug.24(16):3790-3791. Pubmedid: 29798907.
  • Vogelbaum MA, Brewer C, Barnett GH, Mohammadi AM, Peereboom DM, Ahluwalia MS, Gao S. First-in-human evaluation of the Cleveland Multiport Catheter for convection-enhanced delivery of topotecan in recurrent high-grade glioma: results of pilot trial 1. J Neurosurg. 2018 Apr.1-10. Pubmedid: 29652233.
  • Vogelbaum MA. Personalized therapeutic delivery in the neurosurgical operating room. Proc Natl Acad Sci U S A. 2018 09.115(36):8846-8848. Pubmedid: 30127023. Pmcid: PMC6130357.
  • Kruser TJ, Vogelbaum MA. Primary medical therapy for BRAF-mutant melanoma brain metastases-is this good enough?. Lancet Oncol. 2017 Sep.18(9):e508. Pubmedid: 28884696.
  • Sharma M, Jia X, Ahluwalia M, Barnett GH, Vogelbaum MA, Chao ST, Suh JH, Murphy ES, Yu JS, Angelov L, Mohammadi AM. First follow-up radiographic response is one of the predictors of local tumor progression and radiation necrosis after stereotactic radiosurgery for brain metastases. Cancer Med. 2017 Sep.6(9):2076-2086. Pubmedid: 28776956. Pmcid: PMC5603831.
  • Gittleman H, Lim D, Kattan MW, Chakravarti A, Gilbert MR, Lassman AB, Lo SS, Machtay M, Sloan AE, Sulman EP, Tian D, Vogelbaum MA, Wang TJC, Penas-Prado M, Youssef E, Blumenthal DT, Zhang P, Mehta MP, Barnholtz-Sloan JS. An independently validated nomogram for individualized estimation of survival among patients with newly diagnosed glioblastoma: NRG Oncology RTOG 0525 and 0825. Neurooncol. 2017 May.19(5):669-677. Pubmedid: 28453749. Pmcid: PMC5464437.
  • Nayak L, DeAngelis LM, Brandes AA, Peereboom DM, Galanis E, Lin NU, Soffietti R, Macdonald DR, Chamberlain M, Perry J, Jaeckle K, Mehta M, Stupp R, Muzikansky A, Pentsova E, Cloughesy T, Iwamoto FM, Tonn JC, Vogelbaum MA, Wen PY, van den Bent MJ, Reardon DA. The Neurologic Assessment in Neuro-Oncology (NANO) scale: a tool to assess neurologic function for integration into the Response Assessment in Neuro-Oncology (RANO) criteria. Neurooncol. 2017 May.19(5):625-635. Pubmedid: 28453751. Pmcid: PMC5464449.
  • Cabrera AR, Kirkpatrick JP, Fiveash JB, Shih HA, Koay EJ, Lutz S, Petit J, Chao ST, Brown PD, Vogelbaum M, Reardon DA, Chakravarti A, Wen PY, Chang E. Radiation therapy for glioblastoma: Executive summary of an American Society for Radiation Oncology Evidence-Based Clinical Practice Guideline. Pract Radiat Oncol. 2017 Mar.6(4):217-225. Pubmedid: 27211230.
  • Mohammadi AM, Schroeder JL, Angelov L, Chao ST, Murphy ES, Yu JS, Neyman G, Jia X, Suh JH, Barnett GH, Vogelbaum MA. Impact of the radiosurgery prescription dose on the local control of small (2 cm or smaller) brain metastases. J Neurosurg. 2017 Mar.126(3):735-743. Pubmedid: 27231978.
  • Miller JA, Kotecha R, Ahluwalia MS, Mohammadi AM, Chao ST, Barnett GH, Murphy ES, Vogelbaum MA, Angelov L, Peereboom DM, Suh JH. Overall survival and the response to radiotherapy among molecular subtypes of breast cancer brain metastases treated with targeted therapies. Cancer. 2017 Jun.123(12):2283-2293. Pubmedid: 28192598.
  • Kotecha R, Damico N, Miller JA, Suh JH, Murphy ES, Reddy CA, Barnett GH, Vogelbaum MA, Angelov L, Mohammadi AM, Chao ST. Three or More Courses of Stereotactic Radiosurgery for Patients with Multiply Recurrent Brain Metastases. Neurosurgery. 2017 Jun.80(6):871-879. Pubmedid: 28327948.
  • Kim JM, Miller JA, Kotecha R, Xiao R, Juloori A, Ward MC, Ahluwalia MS, Mohammadi AM, Peereboom DM, Murphy ES, Suh JH, Barnett GH, Vogelbaum MA, Angelov L, Stevens GH, Chao ST. The risk of radiation necrosis following stereotactic radiosurgery with concurrent systemic therapies. J Neurooncol. 2017 Jun.133(2):357-368. Pubmedid: 28434110.
  • Miller JA, Kotecha R, Barnett GH, Suh JH, Angelov L, Murphy ES, Vogelbaum MA, Mohammadi A, Chao ST. Quality of Life following Stereotactic Radiosurgery for Single and Multiple Brain Metastases. Neurosurgery. 2017 Jul.81(1):147-155. Pubmedid: 28327994.
  • Wen PY, Chang SM, Van den Bent MJ, Vogelbaum MA, Macdonald DR, Lee EQ. Response Assessment in Neuro-Oncology Clinical Trials. J Clin Oncol. 2017 Jul.35(21):2439-2449. Pubmedid: 28640707. Pmcid: PMC5516482.
  • Sharma M, Juthani RG, Vogelbaum MA. Updated response assessment criteria for high-grade glioma: beyond the MacDonald criteria. Chin Clin Oncol. 2017 Aug.6(4):37. Pubmedid: 28841799.
  • Alvarado AG, Thiagarajan PS, Mulkearns-Hubert EE, Silver DJ, Hale JS, Alban TJ, Turaga SM, Jarrar A, Reizes O, Longworth MS, Vogelbaum MA, Lathia JD. Glioblastoma Cancer Stem Cells Evade Innate Immune Suppression of Self-Renewal through Reduced TLR4 Expression. Cell Stem Cell. 2017 Apr.20(4):450-461.e4. Pubmedid: 28089910. Pmcid: PMC5822422.
  • Albert NL, Weller M, Suchorska B, Galldiks N, Soffietti R, Kim MM, la Fougère C, Pope W, Law I, Arbizu J, Chamberlain MC, Vogelbaum M, Ellingson BM, Tonn JC. Response Assessment in Neuro-Oncology working group and European Association for Neuro-Oncology recommendations for the clinical use of PET imaging in gliomas. Neurooncol. 2016 Sep.18(9):1199-1208. Pubmedid: 27106405. Pmcid: PMC4999003.
  • Silva D, Grabowski MM, Juthani R, Sharma M, Angelov L, Vogelbaum MA, Chao S, Suh J, Mohammadi A, Barnett GH. Gamma Knife radiosurgery for intracranial hemangioblastoma. J Clin Neurosci. 2016 Sep.31:147-151. Pubmedid: 27422585.
  • Kotecha R, Vogel S, Suh JH, Barnett GH, Murphy ES, Reddy CA, Parsons M, Vogelbaum MA, Angelov L, Mohammadi AM, Stevens GHJ, Peereboom DM, Ahluwalia MS, Chao ST. A cure is possible: a study of 10-year survivors of brain metastases. J Neurooncol. 2016 Sep.129(3):545-555. Pubmedid: 27456950.
  • Alvarado AG, Turaga SM, Sathyan P, Mulkearns-Hubert EE, Otvos B, Silver DJ, Hale JS, Flavahan WA, Zinn PO, Sinyuk M, Li M, Guda MR, Velpula KK, Tsung AJ, Nakano I, Vogelbaum MA, Majumder S, Rich JN, Lathia JD. Coordination of self-renewal in glioblastoma by integration of adhesion and microRNA signaling. Neurooncol. 2016 May.18(5):656-666. Pubmedid: 26374689. Pmcid: PMC4827035.
  • Murphy ES, Chao ST, Angelov L, Vogelbaum MA, Barnett G, Jung E, Recinos VR, Mohammadi A, Suh JH. Radiosurgery for Pediatric Brain Tumors. Pediatr Blood Cancer. 2016 Mar.63(3):398-405. Pubmedid: 26536284.
  • Cloughesy TF, Landolfi J, Hogan DJ, Bloomfield S, Carter B, Chen CC, Elder JB, Kalkanis SN, Kesari S, Lai A, Lee IY, Liau LM, Mikkelsen T, Nghiemphu PL, Piccioni D, Walbert T, Chu A, Das A, Diago OR, Gammon D, Gruber HE, Hanna M, Jolly DJ, Kasahara N, McCarthy D, Mitchell L, Ostertag D, Robbins JM, Rodriguez-Aguirre M, Vogelbaum MA. Phase 1 trial of vocimagene amiretrorepvec and 5-fluorocytosine for recurrent high-grade glioma. Sci Transl Med. 2016 Jun.8(341):341ra75. Pubmedid: 27252174. Pmcid: PMC6707068.
  • Zimmerman AL, Murphy ES, Suh JH, Vogelbaum MA, Barnett GH, Angelov L, Ahluwalia M, Reddy CA, Chao ST. Treatment of Large Brain Metastases With Stereotactic Radiosurgery. Technol Cancer Res Treat. 2016 Feb.15(1):186-195. Pubmedid: 25633136.
  • Silver DJ, Sinyuk M, Vogelbaum MA, Ahluwalia MS, Lathia JD. The intersection of cancer, cancer stem cells, and the immune system: therapeutic opportunities. Neurooncol. 2016 Feb.18(2):153-159. Pubmedid: 26264894. Pmcid: PMC4724178.
  • Miller JA, Bennett EE, Xiao R, Kotecha R, Chao ST, Vogelbaum MA, Barnett GH, Angelov L, Murphy ES, Yu JS, Ahluwalia MS, Suh JH, Mohammadi AM. Association Between Radiation Necrosis and Tumor Biology After Stereotactic Radiosurgery for Brain Metastasis. Int J Radiat Oncol Biol Phys. 2016 Dec.96(5):1060-1069. Pubmedid: 27742540.
  • Kotecha R, Zimmerman A, Murphy ES, Ahmed Z, Ahluwalia MS, Suh JH, Reddy CA, Angelov L, Vogelbaum MA, Barnett GH, Chao ST. Management of Brain Metastasis in Patients With Pulmonary Neuroendocrine Carcinomas. Technol Cancer Res Treat. 2016 Aug.15(4):566-572. Pubmedid: 26041398.
  • Otvos B, Silver DJ, Mulkearns-Hubert EE, Alvarado AG, Turaga SM, Sorensen MD, Rayman P, Flavahan WA, Hale JS, Stoltz K, Sinyuk M, Wu Q, Jarrar A, Kim SH, Fox PL, Nakano I, Rich JN, Ransohoff RM, Finke J, Kristensen BW, Vogelbaum MA, Lathia JD. Cancer Stem Cell-Secreted Macrophage Migration Inhibitory Factor Stimulates Myeloid Derived Suppressor Cell Function and Facilitates Glioblastoma Immune Evasion. Stem Cells. 2016 Aug.34(8):2026-2039. Pubmedid: 27145382. Pmcid: PMC5820763.
  • Mansouri A, Mansouri S, Hachem LD, Klironomos G, Vogelbaum MA, Bernstein M, Zadeh G. The role of 5-aminolevulinic acid in enhancing surgery for high-grade glioma, its current boundaries, and future perspectives: A systematic review. Cancer. 2016 Aug.122(16):2469-2478. Pubmedid: 27183272.
  • Arvold ND, Lee EQ, Mehta MP, Margolin K, Alexander BM, Lin NU, Anders CK, Soffietti R, Camidge DR, Vogelbaum MA, Dunn IF, Wen PY. Updates in the management of brain metastases. Neurooncol. 2016 Aug.18(8):1043-1065. Pubmedid: 27382120. Pmcid: PMC4933491.
  • Rogers CL, Perry A, Pugh S, Vogelbaum MA, Brachman D, McMillan W, Jenrette J, Barani I, Shrieve D, Sloan A, Bovi J, Kwok Y, Burri SH, Chao ST, Spalding AC, Anscher MS, Bloom B, Mehta M. Pathology concordance levels for meningioma classification and grading in NRG Oncology RTOG Trial 0539. Neurooncol. 2016 Apr.18(4):565-574. Pubmedid: 26493095. Pmcid: PMC4799683.
  • Vogelbaum MA. The benefit of surgical resection in recurrent glioblastoma. Neurooncol. 2016 Apr.18(4):462-463. Pubmedid: 26869588. Pmcid: PMC4799689.
  • Vogelbaum MA, Hu C, Peereboom DM, Macdonald DR, Giannini C, Suh JH, Jenkins RB, Laack NN, Brachman DG, Shrieve DC, Souhami L, Mehta MP. Phase II trial of pre-irradiation and concurrent temozolomide in patients with newly diagnosed anaplastic oligodendrogliomas and mixed anaplastic oligoastrocytomas: long term results of RTOG BR0131. J Neurooncol. 2015 Sep.124(3):413-420. Pubmedid: 26088460. Pmcid: PMC4584176.
  • Ahluwalia MS, Chao ST, Parsons MW, Suh JH, Wang D, Mikkelsen T, Brewer CJ, Smolenski KN, Schilero C, Rump M, Elson P, Angelov L, Barnett GH, Vogelbaum MA, Weil RJ, Peereboom DM. Phase II trial of sunitinib as adjuvant therapy after stereotactic radiosurgery in patients with 1-3 newly diagnosed brain metastases. J Neurooncol. 2015 Sep.124(3):485-491. Pubmedid: 26245136.
  • Ellingson BM, Bendszus M, Boxerman J, Barboriak D, Erickson BJ, Smits M, Nelson SJ, Gerstner E, Alexander B, Goldmacher G, Wick W, Vogelbaum M, Weller M, Galanis E, Kalpathy-Cramer J, Shankar L, Jacobs P, Pope WB, Yang D, Chung C, Knopp MV, Cha S, van den Bent MJ, Chang S, Yung WK, Cloughesy TF, Wen PY, Gilbert MR. Consensus recommendations for a standardized Brain Tumor Imaging Protocol in clinical trials. Neurooncol. 2015 Sep.17(9):1188-1198. Pubmedid: 26250565. Pmcid: PMC4588759.
  • Vogelbaum MA, Aghi MK. Convection-enhanced delivery for the treatment of glioblastoma. Neurooncol. 2015 Mar.17 Suppl 2:ii3-ii8. Pubmedid: 25746090. Pmcid: PMC4483037.
  • Zadeh G, Khan OH, Vogelbaum M, Schiff D. Much debated controversies of diffuse low-grade gliomas. Neurooncol. 2015 Mar.17(3):323-326. Pubmedid: 26114668. Pmcid: PMC4483107.
  • Lin NU, Lee EQ, Aoyama H, Barani IJ, Barboriak DP, Baumert BG, Bendszus M, Brown PD, Camidge DR, Chang SM, Dancey J, de Vries EG, Gaspar LE, Harris GJ, Hodi FS, Kalkanis SN, Linskey ME, Macdonald DR, Margolin K, Mehta MP, Schiff D, Soffietti R, Suh JH, van den Bent MJ, Vogelbaum MA, Wen PY. Response assessment criteria for brain metastases: proposal from the RANO group. Lancet Oncol. 2015 Jun.16(6):e270-e278. Pubmedid: 26065612.
  • Mahata B, Biswas S, Rayman P, Chahlavi A, Ko J, Bhattacharjee A, Li YT, Li Y, Das T, Sa G, Raychaudhuri B, Vogelbaum MA, Tannenbaum C, Finke JH, Biswas K. GBM Derived Gangliosides Induce T Cell Apoptosis through Activation of the Caspase Cascade Involving Both the Extrinsic and the Intrinsic Pathway. PLoS One. 2015 Jul.10(7):e0134425. Pubmedid: 26226135. Pmcid: PMC4520498.
  • Rogers L, Barani I, Chamberlain M, Kaley TJ, McDermott M, Raizer J, Schiff D, Weber DC, Wen PY, Vogelbaum MA. Meningiomas: knowledge base, treatment outcomes, and uncertainties. A RANO review. J Neurosurg. 2015 Jan.122(1):4-23. Pubmedid: 25343186. Pmcid: PMC5062955.
  • Healy AT, Vogelbaum MA. Convection-enhanced drug delivery for gliomas. Surg Neurol Int. 2015 Feb.6(Suppl 1):S59-S67. Pubmedid: 25722934. Pmcid: PMC4338487.
  • Thibault I, Chang EL, Sheehan J, Ahluwalia MS, Guckenberger M, Sohn MJ, Ryu S, Foote M, Lo SS, Muacevic A, Soltys SG, Chao S, Gerszten P, Lis E, Yu E, Bilsky M, Fisher C, Schiff D, Fehlings MG, Ma L, Chang S, Chow E, Parelukar WR, Vogelbaum MA, Sahgal A. Response assessment after stereotactic body radiotherapy for spinal metastasis: a report from the SPIne response assessment in Neuro-Oncology (SPINO) group. Lancet Oncol. 2015 Dec.16(16):e595-e603. Pubmedid: 26678212.
  • Chang SM, Wen PY, Vogelbaum MA, Macdonald DR, van den Bent MJ. Response Assessment in Neuro-Oncology (RANO): more than imaging criteria for malignant glioma. Neurooncol Pract. 2015 Dec.2(4):205-209. Pubmedid: 31386074. Pmcid: PMC6664617.
  • Juthani RG, Bilsky MH, Vogelbaum MA. Current Management and Treatment Modalities for Intramedullary Spinal Cord Tumors. CURR TREAT OPTION ON. 2015 Aug.16(8):39. Pubmedid: 26143269.
  • Raychaudhuri B, Rayman P, Huang P, Grabowski M, Hambardzumyan D, Finke JH, Vogelbaum MA. Myeloid derived suppressor cell infiltration of murine and human gliomas is associated with reduction of tumor infiltrating lymphocytes. J Neurooncol. 2015 Apr.122(2):293-301. Pubmedid: 25579983.
  • Hsieh J, Elson P, Otvos B, Rose J, Loftus C, Rahmathulla G, Angelov L, Barnett GH, Weil RJ, Vogelbaum MA. Tumor progression in patients receiving adjuvant whole-brain radiotherapy vs localized radiotherapy after surgical resection of brain metastases. Neurosurgery. 2015 Apr.76(4):411-420. Pubmedid: 25599198.
  • Weil RJ, Mavinkurve GG, Chao ST, Vogelbaum MA, Suh JH, Kolar M, Toms SA. Intraoperative radiotherapy to treat newly diagnosed solitary brain metastasis: initial experience and long-term outcomes. J Neurosurg. 2015 Apr.122(4):825-832. Pubmedid: 25614945.
  • Grabowski MM, Recinos PF, Nowacki AS, Schroeder JL, Angelov L, Barnett GH, Vogelbaum MA. Residual tumor volume versus extent of resection: predictors of survival after surgery for glioblastoma. J Neurosurg. 2014 Nov.121(5):1115-1123. Pubmedid: 25192475.
  • Kaley T, Barani I, Chamberlain M, McDermott M, Panageas K, Raizer J, Rogers L, Schiff D, Vogelbaum M, Weber D, Wen P. Historical benchmarks for medical therapy trials in surgery- and radiation-refractory meningioma: a RANO review. Neurooncol. 2014 Jun.16(6):829-840. Pubmedid: 24500419. Pmcid: PMC4022224.
  • Vogelbaum MA. Towards a genomic definition of completeness of resection?. Neurooncol. 2014 Jan.16(1):2-3. Pubmedid: 24366973. Pmcid: PMC3870827.
  • Gilbert MR, Dignam JJ, Armstrong TS, Wefel JS, Blumenthal DT, Vogelbaum MA, Colman H, Chakravarti A, Pugh S, Won M, Jeraj R, Brown PD, Jaeckle KA, Schiff D, Stieber VW, Brachman DG, Werner-Wasik M, Tremont-Lukats IW, Sulman EP, Aldape KD, Curran WJ, Mehta MP. A randomized trial of bevacizumab for newly diagnosed glioblastoma. N Engl J Med. 2014 Feb.370(8):699-708. Pubmedid: 24552317. Pmcid: PMC4201043.
  • Ahluwalia MS, Vogelbaum MV, Chao ST, Mehta MM. Brain metastasis and treatment. F1000Prime Rep. 2014 Dec.6:114. Pubmedid: 25580268. Pmcid: PMC4251415.
  • Mohammadi AM, Sullivan TB, Barnett GH, Recinos V, Angelov L, Kamian K, Vogelbaum MA. Use of high-field intraoperative magnetic resonance imaging to enhance the extent of resection of enhancing and nonenhancing gliomas. Neurosurgery. 2014 Apr.74(4):339-348. Pubmedid: 24368543.
  • Shiue K, Barnett GH, Suh JH, Vogelbaum MA, Reddy CA, Weil RJ, Angelov L, Neyman G, Chao ST. Using higher isodose lines for gamma knife treatment of 1 to 3 brain metastases is safe and effective. Neurosurgery. 2014 Apr.74(4):360-364. Pubmedid: 24448185.
  • Lin NU, Lee EQ, Aoyama H, Barani IJ, Baumert BG, Brown PD, Camidge DR, Chang SM, Dancey J, Gaspar LE, Harris GJ, Hodi FS, Kalkanis SN, Lamborn KR, Linskey ME, Macdonald DR, Margolin K, Mehta MP, Schiff D, Soffietti R, Suh JH, van den Bent MJ, Vogelbaum MA, Wefel JS, Wen PY. Challenges relating to solid tumour brain metastases in clinical trials, part 1: patient population, response, and progression. A report from the RANO group. Lancet Oncol. 2013 Sep.14(10):e396-e406. Pubmedid: 23993384.
  • Lin NU, Wefel JS, Lee EQ, Schiff D, van den Bent MJ, Soffietti R, Suh JH, Vogelbaum MA, Mehta MP, Dancey J, Linskey ME, Camidge DR, Aoyama H, Brown PD, Chang SM, Kalkanis SN, Barani IJ, Baumert BG, Gaspar LE, Hodi FS, Macdonald DR, Wen PY. Challenges relating to solid tumour brain metastases in clinical trials, part 2: neurocognitive, neurological, and quality-of-life outcomes. A report from the RANO group. Lancet Oncol. 2013 Sep.14(10):e407-e416. Pubmedid: 23993385.
  • Grabowski M, Recinos P, Chen T, Prayson R, Vogelbaum M. Calcifying pseudoneoplasm of the neuraxis overlying the corpus callosum: a case report and review of the literature. Clin Neuropathol. 2013 Nov.32(6):515-521. Pubmedid: 23863347.
  • Agarwal S, Manchanda P, Vogelbaum MA, Ohlfest JR, Elmquist WF. Function of the blood-brain barrier and restriction of drug delivery to invasive glioma cells: findings in an orthotopic rat xenograft model of glioma. Drug Metab Dispos. 2013 Jan.41(1):33-39. Pubmedid: 23014761. Pmcid: PMC3533422.
  • Stockham AL, Ahluwalia M, Reddy CA, Suh JH, Kumar A, Vogelbaum MA, Barnett GH, Murphy ES, Chao ST. Results of a questionnaire regarding practice patterns for the diagnosis and treatment of intracranial radiation necrosis after SRS. J Neurooncol. 2013 Dec.115(3):469-475. Pubmedid: 24045970.
  • Rosman J, Slane S, Dery B, Vogelbaum MA, Cohen-Gadol AA, Couldwell WT. Is there a shortage of neurosurgeons in the United States?. Neurosurgery. 2013 Aug.73(2):354-355. Pubmedid: 23660716.
  • Patel M, Vogelbaum MA, Barnett GH, Jalali R, Ahluwalia MS. Molecular targeted therapy in recurrent glioblastoma: current challenges and future directions. Expert Opin Inv Drug. 2012 Sep.21(9):1247-1266. Pubmedid: 22731981.
  • Vogelbaum MA. Does extent of resection of a glioblastoma matter?. Clin Neurosurg. 2012 Oct.59:79-81. Pubmedid: 22960517.
  • Scott JG, Bauchet L, Fraum TJ, Nayak L, Cooper AR, Chao ST, Suh JH, Vogelbaum MA, Peereboom DM, Zouaoui S, Mathieu-Daudé H, Fabbro-Peray P, Rigau V, Taillandier L, Abrey LE, DeAngelis LM, Shih JH, Iwamoto FM. Recursive partitioning analysis of prognostic factors for glioblastoma patients aged 70 years or older. Cancer. 2012 Nov.118(22):5595-5600. Pubmedid: 22517216. Pmcid: PMC3402652.
  • Galanis E, Wu W, Cloughesy T, Lamborn K, Mann B, Wen PY, Reardon DA, Wick W, Macdonald D, Armstrong TS, Weller M, Vogelbaum M, Colman H, Sargent DJ, van den Bent MJ, Gilbert M, Chang S. Phase 2 trial design in neuro-oncology revisited: a report from the RANO group. Lancet Oncol. 2012 May.13(5):e196-e204. Pubmedid: 22554547.
  • Xu Z, Marko NF, Angelov L, Barnett GH, Chao ST, Vogelbaum MA, Suh JH, Weil RJ. Impact of preexisting tumor necrosis on the efficacy of stereotactic radiosurgery in the treatment of brain metastases in women with breast cancer. Cancer. 2012 Mar.118(5):1323-1333. Pubmedid: 22009460.
  • Neuner EA, Ahrens CL, Groszek JJ, Isada C, Vogelbaum MA, Fissell WH, Bhimraj A. Use of therapeutic drug monitoring to treat Elizabethkingia meningoseptica meningitis and bacteraemia in an adult. J Antimicrob Chemother. 2012 Jun.67(6):1558-1560. Pubmedid: 22357803. Pmcid: PMC3350328.
  • Barnholtz-Sloan JS, Yu C, Sloan AE, Vengoechea J, Wang M, Dignam JJ, Vogelbaum MA, Sperduto PW, Mehta MP, Machtay M, Kattan MW. A nomogram for individualized estimation of survival among patients with brain metastasis. Neurooncol. 2012 Jul.14(7):910-918. Pubmedid: 22544733. Pmcid: PMC3379797.
  • Tsao MN, Rades D, Wirth A, Lo SS, Danielson BL, Gaspar LE, Sperduto PW, Vogelbaum MA, Radawski JD, Wang JZ, Gillin MT, Mohideen N, Hahn CA, Chang EL. Radiotherapeutic and surgical management for newly diagnosed brain metastasis(es): An American Society for Radiation Oncology evidence-based guideline. Pract Radiat Oncol. 2012 Jul.2(3):210-225. Pubmedid: 25925626. Pmcid: PMC3808749.
  • Vogelbaum MA, Jost S, Aghi MK, Heimberger AB, Sampson JH, Wen PY, Macdonald DR, Van den Bent MJ, Chang SM. Application of novel response/progression measures for surgically delivered therapies for gliomas: Response Assessment in Neuro-Oncology (RANO) Working Group. Neurosurgery. 2012 Jan.70(1):234-243. Pubmedid: 21593697.
  • Thakkar VV, Chao ST, Barnett GH, Susan L, Rasmussen P, Vogelbaum MA, Reddy CA, Jamison B, Suh J. Quality of life after gamma knife radiosurgery for benign lesions: a prospective study. J Radiosurg SBRT. 2012 Jan.1(4):281-286. Pubmedid: 29296328. Pmcid: PMC5658862.
  • Mohammadi AM, Recinos PF, Barnett GH, Weil RJ, Vogelbaum MA, Chao ST, Suh JH, Marko NF, Elson P, Neyman G, Angelov L. Role of Gamma Knife surgery in patients with 5 or more brain metastases. J Neurosurg. 2012 Dec.117 Suppl:5-12. Pubmedid: 23205782.
  • Hunter GK, Suh JH, Reuther AM, Vogelbaum MA, Barnett GH, Angelov L, Weil RJ, Neyman G, Chao ST. Treatment of five or more brain metastases with stereotactic radiosurgery. Int J Radiat Oncol Biol Phys. 2012 Aug.83(5):1394-1398. Pubmedid: 22209150.
  • Balagamwala EH, Suh JH, Barnett GH, Khan MK, Neyman G, Cai RS, Vogelbaum MA, Novak E, Chao ST. The importance of the conformality, heterogeneity, and gradient indices in evaluating Gamma Knife radiosurgery treatment plans for intracranial meningiomas. Int J Radiat Oncol Biol Phys. 2012 Aug.83(5):1406-1413. Pubmedid: 22209151.
  • Guo S, Reddy CA, Chao ST, Suh JH, Barnett GH, Vogelbaum MA, Videtic GM. Impact of non-small cell lung cancer histology on survival predicted from the graded prognostic assessment for patients with brain metastases. Lung Cancer. 2012 Aug.77(2):389-393. Pubmedid: 22542706.
  • Stockham AL, Tievsky AL, Koyfman SA, Reddy CA, Suh JH, Vogelbaum MA, Barnett GH, Chao ST. Conventional MRI does not reliably distinguish radiation necrosis from tumor recurrence after stereotactic radiosurgery. J Neurooncol. 2012 Aug.109(1):149-158. Pubmedid: 22638727.
  • Xu Z, Marko NF, Chao ST, Angelov L, Vogelbaum MA, Suh JH, Barnett GH, Weil RJ. Relationship between HER2 status and prognosis in women with brain metastases from breast cancer. Int J Radiat Oncol Biol Phys. 2012 Apr.82(5):e739-e747. Pubmedid: 22024205.
  • Reardon DA, Wen PY, Alfred Yung WK, Berk L, Narasimhan N, Turner CD, Clackson T, Rivera VM, Vogelbaum MA. Ridaforolimus for patients with progressive or recurrent malignant glioma: a perisurgical, sequential, ascending-dose trial. Cancer Chemother Pharmacol. 2012 Apr.69(4):849-860. Pubmedid: 22037923.
  • Vogelbaum MA, Iannotti CA. Convection-enhanced delivery of therapeutic agents into the brain. Handb Clin Neurol. 2012 Apr.104:355-362. Pubmedid: 22230453.
  • Chao ST, Thakkar VV, Barnett GH, Vogelbaum MA, Angelov L, Weil RJ, Rasmussen P, Reuther AM, Jamison B, Neyman G, Suh JH. Prospective study of the short-term adverse effects of gamma knife radiosurgery. Technol Cancer Res Treat. 2012 Apr.11(2):117-122. Pubmedid: 22335405.
  • Marko NF, Suh JH, Chao ST, Barnett GH, Vogelbaum MA, Toms S, Weil RJ, Angelov L. Gamma knife stereotactic radiosurgery for the management of incidentally-identified brain metastasis from non-small cell lung cancer. J Neurooncol. 2011 Sep.104(3):817-824. Pubmedid: 21431468.
  • Reardon DA, Galanis E, DeGroot JF, Cloughesy TF, Wefel JS, Lamborn KR, Lassman AB, Gilbert MR, Sampson JH, Wick W, Chamberlain MC, Macdonald DR, Mehta MP, Vogelbaum MA, Chang SM, Van den Bent MJ, Wen PY. Clinical trial end points for high-grade glioma: the evolving landscape. Neurooncol. 2011 Mar.13(3):353-361. Pubmedid: 21310734. Pmcid: PMC3064608.
  • van den Bent MJ, Wefel JS, Schiff D, Taphoorn MJ, Jaeckle K, Junck L, Armstrong T, Choucair A, Waldman AD, Gorlia T, Chamberlain M, Baumert BG, Vogelbaum MA, Macdonald DR, Reardon DA, Wen PY, Chang SM, Jacobs AH. Response assessment in neuro-oncology (a report of the RANO group): assessment of outcome in trials of diffuse low-grade gliomas. Lancet Oncol. 2011 Jun.12(6):583-593. Pubmedid: 21474379.
  • Raychaudhuri B, Rayman P, Ireland J, Ko J, Rini B, Borden EC, Garcia J, Vogelbaum MA, Finke J. Myeloid-derived suppressor cell accumulation and function in patients with newly diagnosed glioblastoma. Neurooncol. 2011 Jun.13(6):591-599. Pubmedid: 21636707. Pmcid: PMC3107102.
  • Hsi LC, Kundu S, Palomo J, Xu B, Ficco R, Vogelbaum MA, Cathcart MK. Silencing IL-13Rα2 promotes glioblastoma cell death via endogenous signaling. Mol Cancer Ther. 2011 Jul.10(7):1149-1160. Pubmedid: 21596889. Pmcid: PMC3132296.
  • Siomin V, Lin JL, Marko NF, Barnett GH, Toms SA, Chao ST, Angelov L, Vogelbaum MA, Navaratne K, Suh JH, Weil RJ. Stereotactic radiosurgical treatment of brain metastases to the choroid plexus. Int J Radiat Oncol Biol Phys. 2011 Jul.80(4):1134-1142. Pubmedid: 21683888.
  • Mueller S, Polley MY, Lee B, Kunwar S, Pedain C, Wembacher-Schröder E, Mittermeyer S, Westphal M, Sampson JH, Vogelbaum MA, Croteau D, Chang SM. Effect of imaging and catheter characteristics on clinical outcome for patients in the PRECISE study. J Neurooncol. 2011 Jan.101(2):267-277. Pubmedid: 20563833. Pmcid: PMC2996533.
  • Raychaudhuri B, Vogelbaum MA. IL-8 is a mediator of NF-κB induced invasion by gliomas. J Neurooncol. 2011 Jan.101(2):227-235. Pubmedid: 20577780.
  • Suh JH, Chao ST, Angelov L, Vogelbaum MA, Barnett GH. Role of stereotactic radiosurgery for multiple (>4) brain metastases. J Radiosurg SBRT. 2011 Jan.1(1):31-40. Pubmedid: 29296295. Pmcid: PMC5658898.
  • Murphy ES, Barnett GH, Vogelbaum MA, Neyman G, Stevens GH, Cohen BH, Elson P, Vassil AD, Suh JH. Long-term outcomes of Gamma Knife radiosurgery in patients with vestibular schwannomas. J Neurosurg. 2011 Feb.114(2):432-440. Pubmedid: 20095786.
  • Marina O, Suh JH, Reddy CA, Barnett GH, Vogelbaum MA, Peereboom DM, Stevens GH, Elinzano H, Chao ST. Treatment outcomes for patients with glioblastoma multiforme and a low Karnofsky Performance Scale score on presentation to a tertiary care institution. Clinical article. J Neurosurg. 2011 Aug.115(2):220-229. Pubmedid: 21548745.
  • Ahluwalia MS, Patton C, Stevens G, Tekautz T, Angelov L, Vogelbaum MA, Weil RJ, Chao S, Elson P, Suh JH, Barnett GH, Peereboom DM. Phase II trial of ritonavir/lopinavir in patients with progressive or recurrent high-grade gliomas. J Neurooncol. 2011 Apr.102(2):317-321. Pubmedid: 20683757.
  • Scott JG, Suh JH, Elson P, Barnett GH, Vogelbaum MA, Peereboom DM, Stevens GH, Elinzano H, Chao ST. Aggressive treatment is appropriate for glioblastoma multiforme patients 70 years old or older: a retrospective review of 206 cases. Neurooncol. 2011 Apr.13(4):428-436. Pubmedid: 21363881. Pmcid: PMC3064699.
  • Rogers L, Gilbert M, Vogelbaum MA. Intracranial meningiomas of atypical (WHO grade II) histology. J Neurooncol. 2010 Sep.99(3):393-405. Pubmedid: 20740303.
  • Vogelbaum MA, Leland Rogers C, Linskey MA, Mehta MP. Opportunities for clinical research in meningioma. J Neurooncol. 2010 Sep.99(3):417-422. Pubmedid: 20835750.
  • Koyfman SA, Tendulkar RD, Chao ST, Vogelbaum MA, Barnett GH, Angelov L, Weil RJ, Neyman G, Reddy CA, Suh JH. Stereotactic radiosurgery for single brainstem metastases: the cleveland clinic experience. Int J Radiat Oncol Biol Phys. 2010 Oct.78(2):409-414. Pubmedid: 20133072.
  • Robinson C, Palomo J, Vogelbaum MA. Thin layer chromatography-based assay of O6-methylguanine-DNA methyltransferase activity in tissue. Anal Biochem. 2010 Oct.405(2):263-265. Pubmedid: 20558126.
  • Peereboom DM, Shepard DR, Ahluwalia MS, Brewer CJ, Agarwal N, Stevens GH, Suh JH, Toms SA, Vogelbaum MA, Weil RJ, Elson P, Barnett GH. Phase II trial of erlotinib with temozolomide and radiation in patients with newly diagnosed glioblastoma multiforme. J Neurooncol. 2010 May.98(1):93-99. Pubmedid: 19960228.
  • Marko NF, Angelov L, Toms SA, Suh JH, Chao ST, Vogelbaum MA, Barnett GH, Weil RJ. Stereotactic radiosurgery as single-modality treatment of incidentally identified renal cell carcinoma brain metastases. World Neurosurg. 2010 Mar.73(3):186-193. Pubmedid: 20860956.
  • Bidros DS, Liu JK, Vogelbaum MA. Future of convection-enhanced delivery in the treatment of brain tumors. Future Oncol. 2010 Jan.6(1):117-125. Pubmedid: 20021213.
  • Sampson JH, Archer G, Pedain C, Wembacher-Schröder E, Westphal M, Kunwar S, Vogelbaum MA, Coan A, Herndon JE, Raghavan R, Brady ML, Reardon DA, Friedman AH, Friedman HS, Rodríguez-Ponce MI, Chang SM, Mittermeyer S, Croteau D, Puri RK. Poor drug distribution as a possible explanation for the results of the PRECISE trial. J Neurosurg. 2010 Aug.113(2):301-309. Pubmedid: 20020841.
  • Kunwar S, Chang S, Westphal M, Vogelbaum M, Sampson J, Barnett G, Shaffrey M, Ram Z, Piepmeier J, Prados M, Croteau D, Pedain C, Leland P, Husain SR, Joshi BH, Puri RK. Phase III randomized trial of CED of IL13-PE38QQR vs Gliadel wafers for recurrent glioblastoma. Neurooncol. 2010 Aug.12(8):871-881. Pubmedid: 20511192. Pmcid: PMC2940677.
  • Robinson CG, Palomo JM, Rahmathulla G, McGraw M, Donze J, Liu L, Vogelbaum MA. Effect of alternative temozolomide schedules on glioblastoma O(6)-methylguanine-DNA methyltransferase activity and survival. Brit J Cancer. 2010 Aug.103(4):498-504. Pubmedid: 20628383. Pmcid: PMC2939788.
  • Panicker SP, Raychaudhuri B, Sharma P, Tipps R, Mazumdar T, Mal AK, Palomo JM, Vogelbaum MA, Haque SJ. p300- and Myc-mediated regulation of glioblastoma multiforme cell differentiation. Oncotarget. 2010 Aug.1(4):289-303. Pubmedid: 21304179. Pmcid: PMC3248108.
  • Klenotic PA, Huang P, Palomo J, Kaur B, Van Meir EG, Vogelbaum MA, Febbraio M, Gladson CL, Silverstein RL. Histidine-rich glycoprotein modulates the anti-angiogenic effects of vasculostatin. Am J Pathol. 2010 Apr.176(4):2039-2050. Pubmedid: 20167858. Pmcid: PMC2843491.
  • Wen PY, Macdonald DR, Reardon DA, Cloughesy TF, Sorensen AG, Galanis E, Degroot J, Wick W, Gilbert MR, Lassman AB, Tsien C, Mikkelsen T, Wong ET, Chamberlain MC, Stupp R, Lamborn KR, Vogelbaum MA, van den Bent MJ, Chang SM. Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group. J Clin Oncol. 2010 Apr.28(11):1963-1972. Pubmedid: 20231676.
  • Videtic GM, Reddy CA, Chao ST, Rice TW, Adelstein DJ, Barnett GH, Mekhail TM, Vogelbaum MA, Suh JH. Gender, race, and survival: a study in non-small-cell lung cancer brain metastases patients utilizing the radiation therapy oncology group recursive partitioning analysis classification. Int J Radiat Oncol Biol Phys. 2009 Nov.75(4):1141-1147. Pubmedid: 19327899.
  • Suh JH, Chao ST, Vogelbaum MA. Management of brain metastases. Curr Neurol Neurosci Rep. 2009 May.9(3):223-230. Pubmedid: 19348711.
  • Dasgupta A, Raychaudhuri B, Haqqi T, Prayson R, Van Meir EG, Vogelbaum M, Haque SJ. Stat3 activation is required for the growth of U87 cell-derived tumours in mice. Eur J Cancer. 2009 Mar.45(4):677-684. Pubmedid: 19121577. Pmcid: PMC5424891.
  • Rosenberg LA, Prayson RA, Lee J, Reddy C, Chao ST, Barnett GH, Vogelbaum MA, Suh JH. Long-term experience with World Health Organization grade III (malignant) meningiomas at a single institution. Int J Radiat Oncol Biol Phys. 2009 Jun.74(2):427-432. Pubmedid: 19427553.
  • van den Bent MJ, Vogelbaum MA, Wen PY, Macdonald DR, Chang SM. End point assessment in gliomas: novel treatments limit usefulness of classical Macdonald's Criteria. J Clin Oncol. 2009 Jun.27(18):2905-2908. Pubmedid: 19451418. Pmcid: PMC2702230.
  • Bidros DS, Vogelbaum MA. Novel drug delivery strategies in neuro-oncology. Neurotherapeutics. 2009 Jul.6(3):539-546. Pubmedid: 19560743. Pmcid: PMC5084189.
  • Burgoyne AM, Palomo JM, Phillips-Mason PJ, Burden-Gulley SM, Major DL, Zaremba A, Robinson S, Sloan AE, Vogelbaum MA, Miller RH, Brady-Kalnay SM. PTPmu suppresses glioma cell migration and dispersal. Neurooncol. 2009 Dec.11(6):767-778. Pubmedid: 19304959. Pmcid: PMC2802397.
  • Omay SB, Vogelbaum MA. Current concepts and newer developments in the treatment of malignant gliomas. Indian J Cancer. 2009 Apr.46(2):88-95. Pubmedid: 19346642.
  • Khan MK, Hunter GK, Vogelbaum M, Suh JH, Chao ST. Evidence-based adjuvant therapy for gliomas: current concepts and newer developments. Indian J Cancer. 2009 Apr.46(2):96-107. Pubmedid: 19346643.
  • Vogelbaum MA, Berkey B, Peereboom D, Macdonald D, Giannini C, Suh JH, Jenkins R, Herman J, Brown P, Blumenthal DT, Biggs C, Schultz C, Mehta M. Phase II trial of preirradiation and concurrent temozolomide in patients with newly diagnosed anaplastic oligodendrogliomas and mixed anaplastic oligoastrocytomas: RTOG BR0131. Neurooncol. 2009 Apr.11(2):167-175. Pubmedid: 18779504. Pmcid: PMC2718988.
  • Chao ST, Barnett GH, Vogelbaum MA, Angelov L, Weil RJ, Neyman G, Reuther AM, Suh JH. Salvage stereotactic radiosurgery effectively treats recurrences from whole-brain radiation therapy. Cancer. 2008 Oct.113(8):2198-2204. Pubmedid: 18780319.
  • Kim SH, Chao ST, Toms SA, Vogelbaum MA, Barnett GH, Suh JH, Weil RJ. Stereotactic radiosurgical treatment of parenchymal brain metastases from prostate adenocarcinoma. Surg Neurol. 2008 Jun.69(6):641-646. Pubmedid: 18262258.
  • Kruser TJ, Chao ST, Elson P, Barnett GH, Vogelbaum MA, Angelov L, Weil RJ, Pelley R, Suh JH. Multidisciplinary management of colorectal brain metastases: a retrospective study. Cancer. 2008 Jul.113(1):158-165. Pubmedid: 18459179.
  • Daneshvar H, Nelms J, Muhammad O, Jackson H, Tkach J, Davros W, Peterson T, Vogelbaum MA, Bruchez MP, Toms SA. Imaging characteristics of zinc sulfide shell, cadmium telluride core quantum dots. Nanomedicine (Lond). 2008 Feb.3(1):21-29. Pubmedid: 18393664.
  • Raychaudhuri B, Han Y, Lu T, Vogelbaum MA. Aberrant constitutive activation of nuclear factor kappaB in glioblastoma multiforme drives invasive phenotype. J Neurooncol. 2007 Oct.85(1):39-47. Pubmedid: 17479228.
  • Vogelbaum MA, Sampson JH, Kunwar S, Chang SM, Shaffrey M, Asher AL, Lang FF, Croteau D, Parker K, Grahn AY, Sherman JW, Husain SR, Puri RK. Convection-enhanced delivery of cintredekin besudotox (interleukin-13-PE38QQR) followed by radiation therapy with and without temozolomide in newly diagnosed malignant gliomas: phase 1 study of final safety results. Neurosurgery. 2007 Nov.61(5):1031-1037. Pubmedid: 18091279.
  • Vogelbaum MA. Convection enhanced delivery for treating brain tumors and selected neurological disorders: symposium review. J Neurooncol. 2007 May.83(1):97-109. Pubmedid: 17203397.
  • Jackson H, Muhammad O, Daneshvar H, Nelms J, Popescu A, Vogelbaum MA, Bruchez M, Toms SA. Quantum dots are phagocytized by macrophages and colocalize with experimental gliomas. Neurosurgery. 2007 Mar.60(3):524-529. Pubmedid: 17327798.
  • Lu T, Tian L, Han Y, Vogelbaum M, Stark GR. Dose-dependent cross-talk between the transforming growth factor-beta and interleukin-1 signaling pathways. Proc Natl Acad Sci U S A. 2007 Mar.104(11):4365-4370. Pubmedid: 17360530. Pmcid: PMC1810327.
  • Nathoo N, Ugokwe K, Chang AS, Li L, Ross J, Suh JH, Vogelbaum MA, Barnett GH. The role of 111indium-octreotide brain scintigraphy in the diagnosis of cranial, dural-based meningiomas. J Neurooncol. 2007 Jan.81(2):167-174. Pubmedid: 16850106.
  • Chang S, Vogelbaum M, Lang FF, Haines S, Kunwar S, Chiocca EA, Olivi A, Quinones-Hinojosa A, Parsa A, Warnick R. GNOSIS: guidelines for neuro-oncology: standards for investigational studies--reporting of surgically based therapeutic clinical trials. J Neurooncol. 2007 Apr.82(2):211-220. Pubmedid: 17146595.
  • Rogers LR, Rock JP, Sills AK, Vogelbaum MA, Suh JH, Ellis TL, Stieber VW, Asher AL, Fraser RW, Billingsley JS, Lewis P, Schellingerhout D, Shaw EG. Results of a phase II trial of the GliaSite radiation therapy system for the treatment of newly diagnosed, resected single brain metastases. J Neurosurg. 2006 Sep.105(3):375-384. Pubmedid: 16961129.
  • Chao ST, Barnett GH, Liu SW, Reuther AM, Toms SA, Vogelbaum MA, Videtic GM, Suh JH. Five-year survivors of brain metastases: a single-institution report of 32 patients. Int J Radiat Oncol Biol Phys. 2006 Nov.66(3):801-809. Pubmedid: 16904847.
  • Tendulkar RD, Liu SW, Barnett GH, Vogelbaum MA, Toms SA, Jin T, Suh JH. RPA classification has prognostic significance for surgically resected single brain metastasis. Int J Radiat Oncol Biol Phys. 2006 Nov.66(3):810-817. Pubmedid: 17011454.
  • Vogelbaum MA, Suh JH. Resectable brain metastases. J Clin Oncol. 2006 Mar.24(8):1289-1294. Pubmedid: 16525184.
  • Vogelbaum MA, Angelov L, Lee SY, Li L, Barnett GH, Suh JH. Local control of brain metastases by stereotactic radiosurgery in relation to dose to the tumor margin. J Neurosurg. 2006 Jun.104(6):907-912. Pubmedid: 16776334.
  • Rice TW, Khuntia D, Rybicki LA, Adelstein DJ, Vogelbaum MA, Mason DP, Murthy SC, Blackstone EH. Brain metastases from esophageal cancer: a phenomenon of adjuvant therapy?. Ann Thorac Surg. 2006 Dec.82(6):2042-9, 2049.e1. Pubmedid: 17126108.
  • Kanner AA, Staugaitis SM, Castilla EA, Chernova O, Prayson RA, Vogelbaum MA, Stevens G, Peereboom D, Suh J, Lee SY, Tubbs RR, Barnett GH. The impact of genotype on outcome in oligodendroglioma: validation of the loss of chromosome arm 1p as an important factor in clinical decision making. J Neurosurg. 2006 Apr.104(4):542-550. Pubmedid: 16619658.
  • Siomin V, Angelov L, Li L, Vogelbaum MA. Results of a survey of neurosurgical practice patterns regarding the prophylactic use of anti-epilepsy drugs in patients with brain tumors. J Neurooncol. 2005 Sep.74(2):211-215. Pubmedid: 16193395.
  • Quan AL, Barnett GH, Lee SY, Vogelbaum MA, Toms SA, Staugaitis SM, Prayson RA, Peereboom DM, Stevens GH, Cohen BH, Suh JH. Epidermal growth factor receptor amplification does not have prognostic significance in patients with glioblastoma multiforme. Int J Radiat Oncol Biol Phys. 2005 Nov.63(3):695-703. Pubmedid: 15936158.
  • Chen PG, Lee SY, Barnett GH, Vogelbaum MA, Saxton JP, Fleming PA, Suh JH. Use of the Radiation Therapy Oncology Group recursive partitioning analysis classification system and predictors of survival in 19 women with brain metastases from ovarian carcinoma. Cancer. 2005 Nov.104(10):2174-2180. Pubmedid: 16208705.
  • Nathoo N, Nair D, Phillips M, Vogelbaum MA. Mapping prosody: correlation of functional magnetic resonance imaging with intraoperative electrocorticography recordings in a patient with a right-sided temporooccipital glioma. Case illustration. J Neurosurg. 2005 Nov.103(5):930. Pubmedid: 16305000.
  • Vogelbaum MA. Convection enhanced delivery for the treatment of malignant gliomas: symposium review. J Neurooncol. 2005 May.73(1):57-69. Pubmedid: 15933820.
  • Nathoo N, Cavuşoğlu MC, Vogelbaum MA, Barnett GH. In touch with robotics: neurosurgery for the future. Neurosurgery. 2005 Mar.56(3):421-433. Pubmedid: 15730567.
  • Chahlavi A, Rayman P, Richmond AL, Biswas K, Zhang R, Vogelbaum M, Tannenbaum C, Barnett G, Finke JH. Glioblastomas induce T-lymphocyte death by two distinct pathways involving gangliosides and CD70. Cancer Res. 2005 Jun.65(12):5428-5438. Pubmedid: 15958592.
  • Vogelbaum MA, Masaryk T, Mazzone P, Mekhail T, Fazio V, McCartney S, Marchi N, Kanner A, Janigro D. S100beta as a predictor of brain metastases: brain versus cerebrovascular damage. Cancer. 2005 Aug.104(4):817-824. Pubmedid: 15971200.
  • Chahlavi A, Staugaitis SM, Yahya R, Vogelbaum MA. Intracranial collision tumor mimicking an octreotide-SPECT positive and FDG-PET negative meningioma. J Clin Neurosci. 2005 Aug.12(6):720-723. Pubmedid: 16115558.
  • Rahaman SO, Vogelbaum MA, Haque SJ. Aberrant Stat3 signaling by interleukin-4 in malignant glioma cells: involvement of IL-13Ralpha2. Cancer Res. 2005 Apr.65(7):2956-2963. Pubmedid: 15805299.
  • Siomin VE, Vogelbaum MA, Kanner AA, Lee SY, Suh JH, Barnett GH. Posterior fossa metastases: risk of leptomeningeal disease when treated with stereotactic radiosurgery compared to surgery. J Neurooncol. 2004 Mar.67(1-2):115-121. Pubmedid: 15072456.
  • Nathoo N, Goldlust S, Vogelbaum MA. Epidermal growth factor receptor antagonists: novel therapy for the treatment of high-grade gliomas. Neurosurgery. 2004 Jun.54(6):1480-1488. Pubmedid: 15157306.
  • Suh JH, Vogelbaum MA, Barnett GH. Update of stereotactic radiosurgery for brain tumors. Curr Opin Neurol. 2004 Dec.17(6):681-686. Pubmedid: 15542976.
  • Shaffrey ME, Mut M, Asher AL, Burri SH, Chahlavi A, Chang SM, Farace E, Fiveash JB, Lang FF, Lopes MB, Markert JM, Schiff D, Siomin V, Tatter SB, Vogelbaum MA. Brain metastases. Curr Probl Surg. 2004 Aug.41(8):665-741. Pubmedid: 15354117.
  • Castilla EA, Prayson RA, Kanner AA, Rybicki LA, Tubbs RR, Vogelbaum MA, Barnett GH. Cyclooxygenase-2 in oligodendroglial neoplasms. Cancer. 2003 Oct.98(7):1465-1472. Pubmedid: 14508834.
  • Marchi N, Fazio V, Cucullo L, Kight K, Masaryk T, Barnett G, Vogelbaum M, Kinter M, Rasmussen P, Mayberg MR, Janigro D, Volgelbaum M. Serum transthyretin monomer as a possible marker of blood-to-CSF barrier disruption. J Neurosci. 2003 Mar.23(5):1949-1955. Pubmedid: 12629200. Pmcid: PMC6741971.
  • Kanner AA, Marchi N, Fazio V, Mayberg MR, Koltz MT, Siomin V, Stevens GH, Masaryk T, Aumayr B, Ayumar B, Vogelbaum MA, Barnett GH, Janigro D. Serum S100beta: a noninvasive marker of blood-brain barrier function and brain lesions. Cancer. 2003 Jun.97(11):2806-2813. Pubmedid: 12767094. Pmcid: PMC4135471.
  • Kanner AA, Suh JH, Siomin VE, Lee SY, Barnett GH, Vogelbaum MA. Posterior fossa metastases: aggressive treatment improves survival. Stereot Funct Neuros. 2003 Dec.81(1-4):18-23. Pubmedid: 14742959.
  • Kanner AA, Vogelbaum MA, Mayberg MR, Weisenberger JP, Barnett GH. Intracranial navigation by using low-field intraoperative magnetic resonance imaging: preliminary experience. J Neurosurg. 2002 Nov.97(5):1115-1124. Pubmedid: 12450034.
  • Vogelbaum MA, Rich KM. Caspase-9 transduction overrides the resistance mechanism against p53-mediated apoptosis in U87MG glioma cells. Neurosurgery. 2002 Mar.50(3):673-674. Pubmedid: 11890155.
  • Prayson RA, Castilla EA, Vogelbaum MA, Barnett GH. Cyclooxygenase-2 (COX-2) expression by immunohistochemistry in glioblastoma multiforme. Ann Diagn Pathol. 2002 Jun.6(3):148-153. Pubmedid: 12089724.
  • Rahaman SO, Sharma P, Harbor PC, Aman MJ, Vogelbaum MA, Haque SJ. IL-13R(alpha)2, a decoy receptor for IL-13 acts as an inhibitor of IL-4-dependent signal transduction in glioblastoma cells. Cancer Res. 2002 Feb.62(4):1103-1109. Pubmedid: 11861389.
  • Steinmetz MP, Vogelbaum MA, De Georgia MA, Andrefsky JC, Isada C. Successful treatment of vancomycin-resistant enterococcus meningitis with linezolid: case report and review of the literature. Crit Care Med. 2001 Dec.29(12):2383-2385. Pubmedid: 11801846.
  • Vogelbaum MA, Tong JX, Perugu R, Gutmann DH, Rich KM. Overexpression of bax in human glioma cell lines. J Neurosurg. 1999 Sep.91(3):483-489. Pubmedid: 10470825.
  • Vogelbaum MA, Tong JX, Rich KM. Developmental regulation of apoptosis in dorsal root ganglion neurons. J Neurosci. 1998 Nov.18(21):8928-8935. Pubmedid: 9786998. Pmcid: PMC6793517.
  • Vogelbaum MA, Tong JX, Higashikubo R, Gutmann DH, Rich KM. Transfection of C6 glioma cells with the bax gene and increased sensitivity to treatment with cytosine arabinoside. J Neurosurg. 1998 Jan.88(1):99-105. Pubmedid: 9420079.
  • Vogelbaum MA, Kaufman BA, Park TS, Winthrop AL. Management of uncomplicated skull fractures in children: is hospital admission necessary?. Pediatr Neurosurg. 1998 Aug.29(2):96-101. Pubmedid: 9792964.
  • Tong JX, Vogelbaum MA, Drzymala RE, Rich KM. Radiation-induced apoptosis in dorsal root ganglion neurons. J Neurocytol. 1997 Nov.26(11):771-777. Pubmedid: 9426173.
  • Vogelbaum MA, Tong JX, Higashikubo R, Gutmann DH, Rich KM. Transfection of C6 glioma cells with the bax gene and increased sensitivity to treatment with cytosine arabinoside. Neurosurg Focus. 1997 Nov.3(5):Article3. Pubmedid: 17206779.
  • Vogelbaum MA, Galef J, Menaker M. Factors determining the restoration of circadian behavior by hypothalamic transplants. J Neural Transplant Plast. 1993 Oct.4(4):239-256. Pubmedid: 7948176. Pmcid: PMC2565269.
  • Menaker M, Vogelbaum MA. Mutant circadian period as a marker of suprachiasmatic nucleus function. J Biol Rhythms. 1993 Dec.8 Suppl:S93-S98. Pubmedid: 8274768.
  • Vogelbaum MA, Menaker M. Temporal chimeras produced by hypothalamic transplants. J Neurosci. 1992 Sep.12(9):3619-3627. Pubmedid: 1527601. Pmcid: PMC6575748.
  • Bundy KJ, Vogelbaum MA, Desai VH. The influence of static stress on the corrosion behavior of 316L stainless steel in Ringer's solution. J Biomed Mater Res. 1986 Apr.20(4):493-505. Pubmedid: 3700443.

Grants

Title: Deciphering MDSC Function for GBM Targeting
Sponsor: Nat Institutes of Health
PI (MPI): Vogelbaum, M.
Title: NRG Oncology Network Group Operations Center
Sponsor: Nat Institutes of Health
PI: Vogelbaum, M.

Patient Comments
Overall Satisfaction
5
★★★★★
★★★★★

32 patients rated this provider

The Provider Rating is an average of all responses to specific care provider-related questions from our nationally-recognized Press Ganey Patient Satisfaction Survey. These surveys assess the experience of our patients when visiting us for an Outpatient Clinic, Urgent Care or Virtual Health (Telemedicine) visit. Responses are measured on a scale of 1 to 5 with 5 being the best score.

Patients that are treated in outpatient or hospital environments may receive different surveys, and the volume of responses will vary by question.

Learn more about our patient satisfaction survey

Comments ()

Comments are gathered from specific care provider-related questions from our Patient Satisfaction Survey . The comments are submitted by patients and reflect their views and opinions. Patients are de-identified for confidentiality and patient privacy.

We post both positive and negative comments from the surveys. We do not post comments that are libelous, slanderous, profane, irrelevant or otherwise inappropriate or may risk the privacy of our patients. A “[…]” in the comments below indicates de-identified patient information or comments that are unrelated to the patient’s experience with the visit to the provider, such as comments related to another provider, about the survey itself, or otherwise completely off-topic.

Not all providers will have a star rating or comments. In order to ensure accuracy of our ratings, we only display ratings for providers who have a minimum of 30 completed from the previous 12 months.

Learn more about our patient comments

Provider Ratings and comments are gathered from our nationally-recognized Press Ganey Patient Satisfaction Survey. If a provider does not have ratings or comments listed it can be for several reasons, including:

  • The provider has not yet received the minimum number of patient satisfaction surveys to be eligible for display. We require a minimum of 30 surveys before we post results to ensure that the rating is statistically reliable and a true reflection of patient satisfaction.
  • He or she may be a researcher or other type of provider that does not see patients.
  • The provider practices in a specialty or office that does not use the specified surveys currently used for these ratings.
Learn more about our patient satisfaction survey, ratings and comments